2023-12-31-accounts

Diabetes Research and Wellness Foundation (A Company Limited by Guarantee) Charity Number: 1070607 Company Number: 03496304 Flnanclal Ststements For the year ended 31-Dac-23

Diabetes Research and Wellness Foundation INDEX Page Report of the Trustees 1to33 Independent Auditors, Report 34to37 Statement of Financial Activities 38 Balance Sheet 39 Statement of Cash Flows 40 Notes to the Financial Statements 41to49

iabetes Research Wellness Foundation Diabetes Research and Wellness Foundation (DRWF) (A Company Limited by Guarantee) REPORT & FINANCIAL STATEMENTS For the year ended 31 December 2023 Re8lstered Charlty Number.. 1070607 Company Number: 03496304 THANK YOUI To everyone who has donated, volunteered their time, or undertaken an activity to support Us. Your contribution makes all the difference, meaning that we can carry out awareness, educational programmes and research funding activities to ensure that people with diabetes are 'Staying well untll a cure isfound... THANK YOU! for being part of a powerful community who are intent on investing in a brighter future for all people with diabetes

StrongerTogether #UnitedThroughDiubetes

Tru$t Informatton Creator FR

Oiabere5 Research Wellnpss F4hJrthtlon Message from Co-Founder & Chairman Mike Gretschel l am Mike Gretschel a co-founder and Chairman of DRWF. It has been overfifty years since my dear wlfr called me at the office crylng that "our son has type I diabetes and there is no cure". I trled to calm her, but my words were not enough. Thut was just the beglnning. Ten years later our eldest daughter was also dlagnosed with type l. And now my son's son has type I too. My wife and I have devoted much OA ourfree tlme, with fvmlly andAriends ralslng awareness and the monles necessary to support vltal research. We have been flghtlng the dlabetes battle In the hope of a curefor all these years. We live In hopel As DRWF turned 25 years old in 2023, we paused to reflect on the diabetes landscape. Twenty-five years doesn't seem so very long, but the number of people living with diabetes in the UK has more than doubled in that time. We have worked tirelessly in that time to raise awareness of the different types of diabetes and provide people with the practical Information and tools to support their self-management. As a small team of just 14, we are supported by editorial and research advisory boards, as well as other experts in the field of diabetes and related health, who help us to deliver activities that demonstrate value for money, and most importantly benefit for the dlabetes community. The one thing that binds us all together, is the fact that we are all striving for the same thing. Together, we are Unlted through Dlabetes. Over 25 years, we have supported some of the most innovative research in the UK and around the world. The DRWF Islet Isolation Facilty at the Churchill Hospital, Oxford is pivotal to the UK Islet Transplant Programme, a clinical treatment that support5 a small number of people with type I diabetes through transplant of insulin-producing islet cells. Whilst the clinical element of this treatment is funded by the NHS, and the results for many are impressive, there are limitations that hamper long-term results and prevent more people from benefiting. To address some of these Issues, we funded a xenotransplant programme in the US called the Spring Point Project, which was focused on providing an alternative, sustainable supply of islets for human transplant using pigs. Additionallyi we have supported a plethora of stem cell-based research projects In the hope of finding ways to develop and sustain the islet transplant programme. All the while, providing funds for early career researchers and proof of concept awards which are demonstrating impact for the diabetes community. Some of these examples you can read about in our report or on our webslte. Whilst we have achieved a lot in our 25 years, there is still so much more to do, and we could not do it WSthout YOU I We are so grateful for the longstanding support that we get from donors, sponsors, and partners and are rightly proud of what we have brought to the table, together, for people with diabetes. From the bottom of my heart... Thankyou! Mike Gretschel March 2024 TRUSTEES ANNUAL REPORT FYE2023

OiabÈt¢s RèsÈarch Welifftess Foundadon st Report of the trustees for the year ended 31 December 2023 The trustees are pleased to present their report and message from the Chalrman together with audited financial statements for the year ended 31" December 2023. The financial statements comply wlth the Charities Act 2011; the Companles Act 2006; the Memorandum and Articles of Association and are prepared in accordance with the Flnancial Reporting Standard applicable In the UK and Republic of Ireland IFRS 102 Charities SORPI {effective from 1st January 2015). Our purpose, aims and activities The objects of the charity are,, To assist In the rellef of persons wlth diabetes and any simllar or related dlseases or conditions To ralse public awareness about dlabetes and any simllar or related dlseases or condltlons, thelr Incldence, causes, treatment, avoidance, and relief The focus of our work th As we entered the charity's 25 anniversary year, we took time to reflect on the dlabetes landscape and the charlty's impact over that time. Since inception in 1998, the number of people dlagnosed with dlabetes has more than doubled. Whllst there have been some Incredible advances In treatment and technology in more recent tlmes, whlch improve quality of life and reduce the risk of complicatlons, the number of people Ilvlng with dlabetes continues to rlse at an alarming rate. With more than 5 million people now living with dlabetes In the UK, our work to provide self-management support, 15 more Important than ever. Whilst recognlsSn8 25 years of raising awareness, provlding award-winnlng Diabetes Wellness support pro8rammes, and funding the research that we hope wlll one day flnd a cure, we used thls mllestone anniversary to reflect, rethink and redouble our efforts to ensure that people with diabetes are 'staylng well untila curelsfvund... Our focus In 2023 was to ensure that we offered Wellness programme actlvltles that met need and delivered Impactful outcomes whilst maxlmisln8 opportunity for DRWF to enga8e in partnerships that delivered revenue and benefit for all parties. To thls end, we- Revlewed our Research Strategy to ensure that the awards we offer remain attractive, financially sound, flt for purpose and demonstrate impact for the researcher and the diabetes community. Re-organised our Diabetes Wellness event programme to deliver United Through Dlabetes, a wonderful concept that brings the diabete5 community together with healthcare professionals, public health officials, third sector organlsations and industry partners. All of whom are invested and intent on creating a brighter future for people with diabetes. Restructured our supporter database to ensure that we are taking a personalised approach to stewardship of beneficiaries and donors to improve recruitment and retention rates. Re-organised internally to form a Supporter Services Team which helped to create cost efficiencie5 by enabling us to bring a costly outsourced service In-house. Worked hard to diverslfy fundraising activities to reduce reliance on single income streams- an ongoing process but one which helps to ensure thatthe charity has sustainable income sources and fitforthe ￿ture. TRUSTEES ANNUAL REPORT FYE2023

Diabete5 Research Et Wellne55 Fovnd•Jon Demonstrating public benefit The trustees confirm that they have referred to the general guidance set out by Charity Commission on public benefit. The trustees are satisfied that the Charitws activities meet the principles of public benefit, defined as providlng an identlfiable benefit/s to the publlc, or sectlon of the public, and know of no detriment or harm that may be caused as a result of these activities, which are clearly set out throughout thls report. Volunteers As a small team delivering numerou5 actlvities, we rely on the support of volunteers who partlcipate by helping with administrative tasks in our office; delivering diabetes awareness and information materials; undertake user involvement exercises to help steer and develop our programme activitles; support our educatlonal events and community fundraislng programme or slt on one of our expert panels for research or Information review. The number of volunteers fluttuates each year but Is crucial to helplng us spread the word about the work we do and to support local and national community initlatlves. In addition to ourTrustees, we have an Editorial Advisory Board and a Research Advlsory Board. These are panels of diabetes clinlcians and scientlsts, and other relevant professionals and lay people, all of whom offer their time and expertise voluntarily to ensure that we meet the high standards required of us through our Associatlon of Medical Research Charities IAMRC} accreditation and our commltment to producing clinlcally evidenced health and soclal care information. We wholeheartedly thank all of our volunteers for thelr tlme, expertise and commitment which helps us raise awareness to the charltyi maxlmlse income and malntaln hlgh standards of work. Measuring Impact We use a mixed methods approach to monitor and evaluate our actlvitles In order to ensure that they remain true to purpose and achleve deslred outcomes. Stakeholders and beneflclaries are involved in these evaluatlon processes to ensure the continued relevance, quality, accessiblllty, and effectiveness of activlties. We also undertake Independent evaluatlon with specialist partners for speciflc projetts where impartlal oplnlon and/or additlonal expertise Is required. We keep people with dlabetes at the heart of what we do. Beneficiaries and supporters are Involved In numerous ways to ensure that our support and resources are relevant, accessible and meet need5, helplng to Steer our research prlorities and pro8ramme actlvlties. th Activities & Achievements in 2023- 25 Anniversary Year Awareness, information & support INFORMATION REACH: Whllst recognlsing that a large percentage of exlsting supporters and beneficiaries engagethrough offllne channels, it was important thatwe diverslfy our reach of a wider demographic of the dlabetes community in 2023. We distributed 192,181 campalgn appeals In 2023 to existlng supporters through dlrect mail and reached 29,762 prospectlve beneficiaries and supporters with new awareness campaigns. These appeals are dual purpose raising awareness and providing information about the charity's activities and funding, whilst seeking financial support. They also act as a stewardship tool, helping us to stay connected with long-standin8 supporters of the charlty. Each campalgn provlde5 health information targeted at beneficiarles who could act on the information, either in a preventative way (type 2 diabetes), or to inform and support those Ilvlng with diabetes lall types), in their self-management of the condition. We had an average campaign response rate of Il% acros5 3 streams resulting in over 24,818 responses from across the country. We know from experience that it is likely that many more opened and read the appeal but chose not to make direct contact with us at that time. Historically, we TRUSTEES ANNUAL REPORT FYE2023

Di6bÈtES RÉsÈarth Et Wellness Foundation have seen numbers of people respond to communications that have been distributed many months, or even years, before as they have held onto the information provided for future reference. WEBSITE: Our onllne reach was significantly reduced In 2022 followlng a splke of engagement with our content in 2020/21 due to the pandemlc, There were numerous reasons for this, and our goal was to remedy this situation in 2023, which we did most successfully. Visits to our website increased by 58% from 173,992 to 275,000 visits in the year. Traffic was consistently higher throughout the year instigated by news content and social media campaigns in support of our activities. Updates to our patient information resources started In 2023 with rebranding of our leaflets. These resources are available from our website in pdf and audio format, provlding choice of accessibility. We also offer to provide enlarged print versions of all health and social care resources. There were 8671 downloads of patient informatlon leaflets in the year, with hat Is DlabetesP', 'A healthy Diet and Dlabetes,, and 'Exerclse and Diabetes,, being the most popular. Additionally, 6905 leaflets were dlstrSbuted in hard copy during the year to dlabetes and related healthcare professlonals who order the resources In bulk for dissemination via their cllnics. ¢..) DiabÈies Reseaich & Wellness FoDnd4ilor* .'1 Dlabeios et w￿1￿•$$ Foundaiio A healrl)y DIET and DIABETES Imp￿￿Tht tw p•Op￿4￿•1n¢W1th i por i PLIF The news section of our website is at the top of the Ilst in generatlng trafflc, followed closely by the 'Llvlng wlth Dlabetes, sectlon whlch hosts our Information resources. There was also a significant Interest In our Wellness Programme and th specifically our 25 Annlversary event 'United Through Diabeteg. These three sections alone, accounted for almost 68,000 unlque visits in the year. 1B N¢v1025 The post-event 'Unlted Through Dlobetes, Dlgital Hub and subpa8es, received 2,499 views from 1,550 individual users, who visited more than once. This content was designed to disseminate the workshops and sessions delivered through our Wellness event to a wider audlence who access information online. LIVING WITH DIABETES PODCASTS & VIDEOS: We continued to produce our Living with Diabetes podcasts in 2023 which provide5 another channel through which to access interesting and i educational diabetes content. Whilst these channels are still very much a work in progress, we have had reasonably good engagement during the year with 3,800 visits an increase of 30% on 2022. We alm to develop these channels during 2024, TRUSTEES ANNUAL REPORT FYE2023

Diabetes Resear(h WdlTress foundatlon SOCIAL MEDIA CHANNELS: Social media channels are a great wayto reach a wideraudlencei quicklyi with messages about our actlvities. Whilst we use multiple social media channels, we get greatest engagement in posts about our community activities via Facebook. Combined Facebook and Instagram reach was up around 15Yo in 2023 over 2022 with an equivalent increase in spend in the vear. These channels also drive traffic to our webslte which was almost 60% up on 2022. DIABETES WELLNESS NETWORK: We made changes to the way In which we produce and distribute our Diabetes Wellness Newsletter in the year. This is a subscriber activity which has historically been sent out monthly but due to rislng productlon and postage costs, we Increased pagination and changed distribution to quarterly. We have had good feedback on the addStlonal content contained within the publication and we have not seen a downward trend in volume of renewals, otherthan those anticlpated each year. Importantly, without decreasing value to our supporters and beneficlaries, we were able to reduce the volume of hard copy new51etters clrculated In the year to 52,600 which helped to reduce our costs by around 41%. The intention is to make this newsletter avallable electronically going forward, but through survey of existing subscribers, this audience wish to continue receiving their printed magazine. This is somewhat due to the demographlc proflle of subscriberwlthin this programme, and we expect thls to change as we reach a wider section of the dlabetes communlty who are famlliar and at ease wlth dlgital channels. PATIENT INFORMATION FORUM (PIF) TICK: As members of the Patlent Informatlon Forum, we applied for PIF Tick accreditatlon on our adult health and social care resources. Followlng the robust revlew process operated by PIF we gained the PIF Tick kite mark which Is displayed on our Information resources. This demonstrates that we are a 'trusted information creator, whlch Is an Important way In whlch people seeking our help can recognise that our information 15 relevant, up-to-date, clinically referenced and peer revlewed. Quality In Care Diabetes- award winning Diabetes Wellness events: Self-management Is the cornerstone of dlabetes care, wlth good self- management skllls e55ential to achleve posltlve health outcomes and reduce the risk of associated health compllcations. For the past 23 years, DRWF has been provldlng an annual programme of Diabetes Wellness events that are focused on enabling people to access relevant, evidence-based health informatlon throughout the lifetlme of their lon8-term condition. Whllst provldlng a wide range of diabetes and related-health workshops, interartive sessions and talks, the core prlnclple on whlch this programme Is bullt Is 'peer support., Peer support 15 a valuable resource for people living with diabetes, thelr famlly, frlends and carers and ou r Wellness events provide an opportunity to make new contacts and build new relatlonshlps through mutual acceptance and understandlng, in a safe and inclusive envlronment. Our events inform, inspire and empower people to take ownership of and have more control over theSr health and wellbeing. The diverse learnlng programme on offer helps people to develop knowledge, skills and confidence to address issues that are affecting their health and diabetes self-management. This is especially beneficlal to people who are lonely or isolated and don't have an immediate support network around them. We belleve that this holistic approach supports all round wellbeing and increases learning capacity and resilience, and it is wonderful to see people return to our events year-on-year. th In our 25 anniversary year, our focus was on scaling our award-winning Wellne55 Day to reach a wider and more diverse diabetes audience, increasing footfall and incorporating 'research' into the programme. This gave us the TRUSTEES ANNUAL REPORT FYE2023

Diabetes Researth Es Weiines5 Foundation opportunity to showcase the research that the charity has funded over the last 25 years and demonstrate the impact that this work has had for the diabetes community. This new event was an opportunity to demonstrate that together, we are 'Unlted Through Diabetes.. United Through Dlabetes- the BIG Diabetes Wellness Day 443 On Saturday 16 September, we hosted the inaugural Unlted Through Dlabetes event which saw 443 delegates in attendance. This event was launched to mark the charity's 25 annlversary year to provide a one-stop shop of 'everything diabetes,. The event was supported by Industry partners, and prominent speakers, such as the deputy clinical diabetes lead for England, Professor Partha Kar. The event reached a wide and diverse segment of the diabetes communlty, including families of chlldren wlth type I dlabetes, people with type I, type 2 and other types of diabetes, as well as people working in diabetes and related healthcare. Just one of the highlights of the event was the opportunlty for people to engage wlth DRWF funded researchers, past and present, to understand how the work we have invested in over the i.. past 25 years has delivered Impact/beneflt for people with diabetes. Feedback on the quality and variety of l., workshops and talks on offer was extremely positive and the UTD Dlgltal Hub extended our reach post-event to enable people who couldn't attend to benefit from *. the programme content. 86 Dlabetes Wellness Family Camp th Family Camp took place on 18 August at Whitemoor Lakes In Staffordshlre. We received 34 famlly applicatlons1117 individuals). Whllst our target was to accommodate 60 individuals, we were able to offer places to 86 people from 24 families. There Is a robust trlage process in place for Family Camp 8iven that many children are livlng wlth complex health needs beyond type I diabetes. All those that dld not meet the crlteria for ' We stepped out of our comfort zone, and it brought us together., Opportunity to talk to other children/parents who have type I diabetes, time as (7 family. Famlly Camp were offered places at our Autumn vlrtual Camp in the Cloud. The alm of Camp is to bring families of children with Type I diabetes together in a fun, safe and welcoming environment. The emphasis is on providing fun for the child ren and a little respite for the parents/guardians and perhaps most importantly, providlng a platform for meeting families to share similar experiences of life wlth dlabetes so as to build relationships based on mutual understanding and acceptance. 'Meeting new people. Shar'ing ex eriences. TRUSTEES ANNUAL REPORT FYE2023

Dlabotes Research £ Wellne55 Fosjndation Feellngs before attendlng Camp... HopofiiL Ai)pi eliiTrii¥ivo E.<citid Shy Tirod Intrigued Sl)y Torn Hipj)y Curious xi)ectiiiq Fearful Toi li Conceri)ed Satisfied'Exh'austed Less Anxious (.¢ll'f-Y¥L(' Supp¥rtcd Flin Feelln8s after attendlng Camp... Uplifted Erier9lied Lmotioiial <L,lipved,..., Thrilled Confident ¥1 Elated Pleased 135 Virtual Camp in the Cloud "We have absolutely loved our first ever diabetes campl Thank you so much for having usl The activities were perfectly suited for our girls - we have a 5-year age gap (they are 7 and 12) but they both joined in everything and absolutely loved it alll The dance party was a lot of fun, unfortunately my eldest went into hypo just before but she made up for it later on it. Mi9ny thanks to everyone involved in organising and running today, very much appreciated and so lovely to meet other families with TID" Vlrtual Camp was Introduced during the pandemlc, and due to its success and accessibilityj we have contlnued to offer thi5 fun, online 'Camp'. We had anticipated that we could accommodate between 120 - 150 online attendees and were overwhelmed with the initial response, which saw 55 families (198 indivldualsl reglster their interest. The nature of an online event increases attrition rates so we expected drop out on the day. Forty-seven (47) families went on to complete a full appllcation for 164 individuals, 311 of whom were offered places; 32 families (111 individuals) attended on the day, meaning 32% of families did not attend. This is a similar TRUSTEES ANNUAL REPORT FYE2023

Diabete5 Rewrch Et Wellness Fi>undatlon percentage to previous years. Non-attendance can happen for several reasonsi poor health, unable to travel etc., and so families who can't attend for clear reasons are offered places at the next CITC. A full programme of onllne activities was offered, with a box of arts and crafts, and other materials, supplied beforehand to make the day as interactive and fun as possible. DRWF hosted a Yalking Typel, session for the families where they could raise important questions with our guest speaker, Heather Holland, DSN. Fun was had during the day with the DRWF Dance for Diabetes session which all attendees participated in, led by dance teacher Megan. The day concluded with a closing ceremony and games, 30 Diabetes Wellness Morning- Hartlepool The Diabetes Wellness Morning held In Hartlepool was a new take on the event that the charity has been providing for the last 11 years in the Northeast, Hosted on behalf of DRWF by longtime volunteer, Hayley Hakansson, the event was held to reco8nlse World Diabetes Day and mark the 25th anniversary of the charity. The Wellness Mornin8 was held at the National Museum of the Royal Navy and was attended by 30 people. The alm of the morning was to support people15vlng with diabete5, their famlly, and carers, to provlde practical Information, tools and tips to improve self-management and understanding of the condition whilst providlng an opportunity to spend tlme with diabetes healthcare professionals. The event was organised with the support of the Hartlepool Diabetes Support Group and colleague5 at the North Tees and Hartlepool NHS Foundation Trust. Attendees enjoyed a busy mornlng featuring presentations on diabetes and a question-and-answer 5es5ion from guest D13betes Specialist Nurses Julle Sinclair and Patricia Lowther. Hayley said: Everyone attending the event said how warm and welcoming the Wellness Morning was and they felt they had learned something new, In addition to refreshing thelr knowledge of helpful tlps for living with diabetes." In the build-up to the event Hayley promoted the Wellness Morning with an appearance on the Radio Hartlepool breakfast show, talking to presenter Jason Anderson about her voluntary roles In her local community and encouraging people with diabetes to attend the Diabetes Wellness Morning. Research Funding Programme Each year, we issue Calls for Applications In respect of our 3-year Clinical, Non-clinical and Pump Priming award5. DRWF Fellowships provide the necessary funding to support Early Career Researchers IECR) whlch is vita Ily Important to ensure that clinical and scientif ic talent stays a nd develops within the diabetes medical research community. ECR'5 represent a young and diverse research population, and provide a constant flow of talent, new ideas and new skills. Some of them will 80 on to be the senlor diabetes researchers of the future, so with very few funding awards available to this vital community, the DRWF awards are lucrative and well positioned to attract the best and brightest young researchers. TRUSTEES ANNUAL REPORT FYE2023

Di•betes RèsÈaich Ep Wollness Foundation Our Pump Prlming stream is a proof-of concept funding channel, which aims to produce translational pilot study data that goes on to leverage higher value, longer term funding from other organlsations to take the research conducted to the next level. The DRWF annual funding round is offered through open competition, and as such, enables funded researchers to access support for both indirect and direct costs of research via the Charity Research Support Fund ICRSF) and NIHR Cllnical Research Networks ACORD agreement. Instttutional and discretionary awards are available when funds allow. Contract funding of key personnel within the DRWF Human Islet Isolatlon Facility at the Churchill Hospital, Oxford is subjectto proposal and revlewed on a multi- year rolling contract basis. DRWF Is a member of the Assoclation of Medical Research Charlties (AMRCI, a membership body representing the leadlng medical and health research charlties who deliver high-quality research that saves and improves Ilves. Working wlth member charities and partners, AMRC aims to support voluntary sector effectiveness and advance medical research by developlng best practice, provldlng informatlon and guidance, Improvlng publlc dlalogue about research and science, and Influencln8 government. As a member, we subscrlbe to AMRC'S crlterla forthe use of peer revlew for allocatlng fundin8 and support AMRC position statements on the payment of indlrect costsln unlversltles and the use of animals In medlcal research which seeks to replace, reflne and reduce the use of anlmals13Rsl In research. We operate a rlgorous peer revSew process by whlch our Research Advlsory Board (RAB), clinlcal and sclentiflc experts in the fleld of diabetes and related health, asse55 appllcatlons and reports to ensure that only the hlghest quallty and most effectlve research, carrled out using good or best practlce methodologles, receives DRWF fundlng. Clalre Levy - Ilvlng wlth T2 Dlabetes Funding research into new treatments and new technologies has transformed the lives of people living with allforms of diabetes Includlng myself as someone with Type 2 Diabetes. DR WF has funded some amazing research over the last 24 years, made posslble by the very generous donations of our supporters, which has really advanced our knowledge of the different types of diabetes and how to manage and treat it. We will onlyfind a cure through research and your gift could moke all the dlfference." 4ESEARCH Research Advlsory Board Strategy Day The charlty's Research Advisory Board (RAB) met in March to review current fundin8 Streams and conslder whether awards are delivering value for money, for DRWF, the researcher/institution, and perhaps most Importantlyforthe diabetes ¢ommunlty. Past and currently funded researchers were Invited to present to the RAB from across Fellowship, Pump Priming and Contract Funding streams. The RAB were Impressed by the results that have been seen in all strand5 of fundin8 whetherthat be Pump Priming funding collecting translational pilot study data which has gone on to prove a new concept and leveraged additional funding for a wider body of work to be undertaken, or career progression which has helped develop and retaln expertise in the dlabetes research arena, whilst leveraging higher value multl-year funding for further work. The Strategy Day resulted In a recommendation to the harity's Board of Trustees to uplift Fellowship awards to ensure that they remain attractive and competitive with increasing salarles and consumable costs. This was approved by the Board and will be offered with the next call for applicatlons for Fellowshlp grants. The discussions and information collected at the Strategy Day enabled the update and publication of the charity's Research Strategy for 2024-26. 10 TRUSTEES ANNUAL REPORT FYE2023

Diabete5 Researth ty Wellness FOUnd￿On Diabetes Research Wellness Foundation searc Strategy 2 24-26 P2 JSJ RESEARCH Diabetes Research & Wellness Foundation TRUSTEES ANNUAL REPORT FYE2023

OiabetÈs Research I￿URe$s Foundatio Pump Priming Awards Calls for applications were Issued In September 2023 for Pump Prlmlng Awards to be taken up In 2024. A total of 20 applicatlons were received from which six research awards were made with a total value of £119,982. The DRWF research programme is designed to support bright young researchers, as well as established Institutions, as they strive to makethe klnd of Ilfe-changing breakthrough our diabetes community Is hoping for. Pump Priming awards considered 'proof of concept, and are either Cllnical or Non-clinical in nature. Successful projects are funded for up to two year's duration, to the value of £20,CQO. No-cost extensions to the term may be considered. Nottingham Trent Dr Adalkala Antonysunll University Nottingham Trent Universltv £20,000 Tltle: Integrated omlc5 to Identlfy the epltranscrlptomlc Interartlons between methyl modlflcatlons of mature mlRNAs and tmnscrlptome in placenta due to mlcronutrlent IB12J defl¢lency promotlng dlabete5 In pregnancy ' I Lay Summary: Obesity in pregnancy has adverse effects on both mother and baby and predlsposes them to heart diseases later In life. Women of chlld- bearlng age, pregnant, lactating and women adherlng to vegan diet are at much hlgher rlsk of B12 deficiency, and thelr offsprlng are at elevated rlsk of low blrth weight and preterm blrth. This led to significant Interest in understandin8 the maternal dlet durin8 pre8nancy. My research showed that pregnant women with low B12 have higher sugar and fat levels in the blood and develop more body fat, whSch are slgns of hlgher risk for heart diseases in later life. However, the causal reason is unknown. B12 Is one of the key mlcronutrlents turning the blological swltch on/off for the methylation process, which is responsible for efficient funrtioning of small RNA molecules called microRNA that control genes and cellular process. Here I propose that when B12 levels are deficient, the methyl groups normally added to the microRNA are reduced. This results In dysfunctlonal microRNAs which could profoundly change gene/proteln products and contribute to disease development. The aim is to characterise the methylation sites and Identify the gene targets of microRNAs at the tissue level caused by low B12 using advanced technologies, This approach will identify new pathways affected and detect new targets that could enable tailored therapies in specific patient subgroups to treat diabetes. Benefits are anticipated to enhance the potential for the individualized health care and management of patients with diabetes durlng pregnancy. 12 TRUSTEES ANNUAL REPORT FYE2023

Oioberes Research Et WellnÈ55 Foundation Dr Steven Millership Imperial College London £20,000 rial Co lege Tltle: Repurposing epldrugsfor Aunrtionul enhancement oAhuman puncreatic beta cells Lay Summary: Insulin-secreting beta cells of the pancreas are what are I,: destroyed or become dysfunctional In dlabetes. To restore this functionality, methods have previously Included to transplant isolated islets from donor patients, however thls ha5 been met with problems of survival of lifelong immune suppresslon for the patient, and the survival of the implanted islets themselves. Several research groups have made pioneerin8 progress over the last decade by uslng stem cells originally from the patient, that have a capaclty to become any cell in the body and generatin8 beta cell "like" cells uslng a cocktail of various compounds over multiple stages of beta cell development in the laboratory, Wh3t these cells lack however is their'incomplete" levels of maturity to become a fully functional beta cell, as measured by the amount of insulin produced and their capacity to secrete it into the bloodstream. We hypothesise that the m15slng element are pathways that regulates the expression of key beta cell genes land therefore beta cell maturation) in the body, known as epigenetic pathways. We will screen a large number of commercially available compounds that target these epigenetic pathways known as "epidrugs" and assess their ability to enhance human beta cell maturation In a cellular model system. Our goal Is to Interrogate the role that these novel epigenetic pathways have on beta cell functlonal maturation and ultimately to assess thelr abillty to enhance the functionality of stem cell-derived beta cells prior to transplantation into patlents with diabetes. Dr Ellzabeth Haythorne Edlnburgh Universlty £20,000 114. III-L.L)INIIUII(yl I Tltle: Does portlal Inhibitlon of glucokinase protert human pancreatlc beto<ells agalnst glucotoxlclty and glucollpotoxlcltyP Lay Summary: All forms of diabetes are characterised by a chronically elevated level of blood glucose Ichronic hyperglycaemia, or high blood glucose), which results from Insufficient secretlon of insulin from the P-cells of the pancreas. Type 2 diabetes Is a pro8resslve dlsease in which elevated blood glucose gradually damages the @-cell so that they release even less insulln, which leads to higher blood glucose levels and therefore further P-cell damage. Attime of type 2 dlabetes diagnosis, It 15 often found that an individual's capacity to produce adequate amounts of insulin to maintain healthy blood glucose levels has declined by as much as 50%. This inexorable decline in F-cell function leads to devastating secondary complications, such as heart, eye and kldney disease. Although the current therapeutic strategies available for type 2 diabetes can reduce blood glucose either by enhancing insulin release Isulphonylureas, GLP-I receptor agonists) or by increasing glucose clearance from the blood (insulin, metformin), none of these therapies provide any long-term benefit regarding maintaining F-cell health and insulin secretion. 13 TRUSTEES ANNUAL REPORT FYE2023

*, ¢.) Dlabete5 Researth Er WelLne55 Fountlatlon In people without diabetes, a rise in blood Elucose cause5 glucose from the blood to be taken up bythe P-cell where it is broken down by metabolism to produce a molecule called adenosine triphosphate (ATP), which is needed to stimulate insulin release. lft contrast, when blood glucose is chronically elevated, too much glucose is metabolised by the P-cell and eventually causes "blockages" in the metabolic pathway. These -blockages" mean that glucose can no longer be metabolised to produce enough ATP to cause insulin secretion. Th us, this proposal will investigate if the F-cell can be protected agalnst the detrimental effects of chronic hyperglycaemia by lowering the amount of glucose which is metabolised by the cell down to the same level as which occurs in people without diabete5. This novel approach will prioritise maintalning, or restoring, F-cell health and Insulin secretion whlch will greatly reduce the risk of developing debilitating secondary compllcations. James Russ-sllsby Unlversity of Exeter £20,000 Tltle: Gene dlscovery In tmnslent neonatal dlabete5 to galn new In51ghts Into beta- iversity cell development andfvnctlon Lay Summary: Pancreatlc beta cells make Insulln, which controls blood sugar levels. When beta cells cannot make enough Insulin, it leads to diabetes, a chronic and common condition affecting mllllons worldwlde, The alm of our project is to provide a deeper understanding of how beta cells funct5on and develop, We wlll study indlviduals with rare types of diabetes caused by a slngle genetlc defect. Thls helps us to better understand how beta-cells work by allowing us to look at what happens when a single pathway is broken, offering a wlndow Into the broader functloning of beta cells. The type of diabetes we will Investigate is transient neonatal diabetes mellltus (TNDM). TNDM is dlagnosed In babies who are unable to produce enough insulin during their development before birth and in early life. Unlquely, these children temporarlly regain the ability to produce enough insulin in chlldhood but are then re-diagnosed wlth diabetes later, usually In adolescence or early adulthood. Studying these babSes, therefore, allows us to galn new informatlon on the function and development of beta-cells through time. We will look for new genetSc defects causing TNDM to flnd the key genes responsible for the disease. We will use a powerful genetic technique called whole genome sequenclng. This allows usto read all ofthe person's DNA, meanin8 we can comprehensively look for the defects that cause the diabetes in people with TNDM. We have already ruled out all the known causes and selected indlviduals who have the strongest features of TNDM, meaning we are very likely to flnd new 8enes. Our findings will provlde key new Informatlon on the pathways that govern beta cell functlon and development. This is the crucial first step towards identifyin8 new drug targets for diabetes, bringing us a step closer to better management and treatment of thi5 condition, Dr Lazaros Foukas University College London £19,997 Title: Novel molecular determlnants ofbmwn adipose tlssue inflummatlon In obeslty and glucose dysmetobolism Laysummary: Poor nutrition and population ageingarethe maln contrSbutors to the current global epidemlc of obeslty and type 2 dlabetes. A pathological process underlying the development of these conditions is chronic Inflammation of the adipose tissue. 14 TRUSTEES ANNUAL REPORT FYE2023

Diabetes Re5ear(h Wdlne55 FOUnda￿on There are two main types of adipose tissue: white adipose tissue that stores energy in the form of fat, and brown adipose tissue that contalns a unlque type of mitochondria {cellular organelles that produce energy), whlch can dlssipatethe energyfrom fat and glucose as heat. Inflammation affects both the white adiposetissue and the brown adlpose tissue. Our research has shown that dietary fatty acids actlvate Innate immune slgnalllng pathways assoclated with Inflammation and it aims to demonstrate that certain innate immune pathway components can be manipulated in a manner that promotes the energy dlsslpating activity of the brown adipose tissue. This demonstration would provlde proof-of-principle that pharmacologlcal interventions altering the activity of nnate immune Inflammatory pathways can be used therapeutically to promote energy expenditure in a way that reduces body wei8ht, Improves insulin sensitivlty and prevents or ameliorates type 2 dlabetes. Dr Kleopatra Alexladou Imperial College London £19,985 Imperial College Title: Semoglutlde Improves atherosclerosls vla an antl-lnflammotory octlon Independent oAweight loss Lay Summary: The majority of people wlth type 2 dlabetes Ilve also with overwei8ht or obesity. One third of people living wlth dlabetes are affected by cardiovascular dlsease, namely heart attacks and strokes. This is due to build up of atherosclerosis plaques (accumulations of fats, cholesterol and Immune cells) in artery walls. These plaques can cause arteries to narrow, blockln8 the blood flow and leadln8 to a lack of blood supply e.g. to the heart (causin8 heart attacks) orto the braln (causing strokes). Semaglutide Is a medScation based on gut hormones and it was initially approved for the treatment of dlabetes. Sema8lutlde is now also Ilcensed for weight loss. Some studles have shown beneflclal effects for the cardiovascular system although the exact mechanism Is not fully understood. Inflammation, where the immune system is actlvated to get rid of irritants and Infection, Is a normal process that exist5 to get rid of these irritants. Low grade inflammatlon is also associated with obeslty, type 2 diabetes and atherosclerosls. My hypothesis is that semaglutide has a beneficlal cardlovascular profile via reducing Inflammation and thereby slowing down atheroscleros15 and that this Is a dlrect effect of sema8lutlde and not merely a consequence of welght 1055. Islet Cell Research & Transplant DRWF has made a considerable contribution to the funding of Islet cell research and transplant in the UK and around the world. The DRWF Human 151et Isolation Facility at Churchill Hospital, Oxford plays a pivotal role in providing islets for research and transplant as part of a national treatment programme, the clinical element of which is funded by the NHS. IINIVFRSITY OF OXFORD Three personnel are funded withln the facillty (around 30% of facility staff): Lab Manager Deputy Facility Manager (post doc researcher) Islet Transplant Administrator We maintained our contract funding awards at the DRWF Islet Isolation Facillty, Churchill Hospital, Oxford. These 15 TRUSTEES ANNUAL REPORT FYE2023

Diabetes Rèsearch Wellne55 Foundation posts are funded for between 3-5 year51 givlng continuity and stability to the indlvidual post holders and wider facility/teams. This is vitally important to ensure sustainability of expertise within the research group, given that this facllity works on rotation to isolate islet cells for human transplant, as well as supply islets for research across the UK and Europe. The Deputy Facility Manager post became vacant in the early part of 2023 with the new post- holder recruited from I, December. Impact report from the Director of the DRWF Islet Isolation Facility Churchill Hospital, Oxford by Professor Paul Johnson 2023 saw pancreas donor rates in the UK return to similar numbers to pre-COVID levels, and many of the COVID- precautions being relaxed. Our hospital maintained strlct mask-wearing for part of the year and our team has adapted well to the benefits of hybrid working with online working for many of our meetlngs having become the norm. As observed in many scientific instltutions currently, retention of junior staff was a challenge, but we were fortunate to maintain an enthusiastic and able workforce for our cllnicallsolatlon and research programmes. In December 2023, we were delighted to appoint Ahmad Kobiita as our new Deputy-Facility Manager. Ahmad came to us from Zurich, where he gained considerable experience as a post-doctoral scientist in islet biology. This report provides a summary of our Islet allo-transplant, islet auto-transplant, and islets-for-research programmes, as well as providlng an update of our Involvement with the Vertex Stem-cell derived islet transplant trlals. Islet Allo-tran5plantatlon Our allo-isolation programme had a successful year overall. We malntained our establlshed alternate weekly rota with King's in London for the first 5 months of the year, but unfortunately from June 2023, the Klng's lab had to temporarlly close due to a contamlna6on issue and remained closed for the rest of the year. Thls unexpected closure increased the pressure on Oxford and Edinburgh Islet Isolation Facilitles. However, between January 2023 and December 2023, the DRWF Islet1501ation Facllity performed 19 clinical islet isolatlons for allogenlc use, 10 of which met the UK agreed release criteria for transplantation. Thls is a conversion rate of 53% (international average conversion is about 30%). During 2023, we established a new satelllte beta-cell replacement clinic in Leicester which has been productive for Islet referrals. This covers the East Midlands catchment area and complements our long- established clinic in Birmingham which covers the West Midlands. We are looking to establish a similar satellite arrangement at the Royal Free In London. We continued to promote strongly the importance of an individual patlent-tailored approach to beta-cell replacement, offering an integrated clinical service comprising state-of-the art insulln technology, whole pancreas transplantation, and islet transplantatlon. This enables every patient to be offered the very best treatment available for them. Islet Auto-transplantatlon Our NHS-commissioned total pancreatectomy with islet auto-transplantation (TPIAT) programme for chronlc pancreatitis is well establlshed now and we have achieved excellent outcomes. Indeed, we presented our optimised TPIAT islet 1501ation protocol at the International Pancreas and Islet Transplant Association (IPITA) Congress in San Diego in October 2023. We aim to undertake one TPIAT per month. However, the recurrent industrlal action during the year impacted service delivery. In 2023 therefore, the DRWF Islet Isolation Facility performed 4 clinical islet isolations for autologous use. All 4 of these islet preparations were transplanted. We are now in the process of applyin8 for NHS-commi5slonlng for TPIAT in children, somethlng that our expertise in Oxford makes us well placed to provlde for the UK. 16 TRUSTEES ANNUAL REPORT FYE2023

Diabete5 Research Etr WelLne55 Foufidation Research Islet Provision The DRWF Isolation Facility in Oxford contlnues to be the UK Islet Resource Centre providing human islets for research to a network of type l and type 2 diabetes researchers. In 2023, our team distributed 2.2 million islet equivalents IIEQ- the internatlonal standardised way of counting islets} from 11 islet preparations. The 'lncreasing the Number OA Organs Availablefvr Research, (INOARI initiative is now established, enabling donor organs from donors with diabetes to be retrieved routinely from across the UK for research purposes. The Oxford DRWF Islet Isolatlon team continues to lead the '151et Platform, for the related Quality in Organ Donation (QUODI with responsibility for isolating and distributin8 islets for research from these rare pancrease5. During the year, theteam has had a substantial number of research outputs, including 6 presentations at the 2023 IPITA Congress. Vertex Stem-cell Derlved Islet Trlals In September 2023, Oxford was opened as the first slte In the UK (and one of only a handful In Europe) for the Vertex 880 and Vertex 264 stem-cell derived Islet transplant trlals. The i nitlal Internatlonal data for these trlals is encouragln& and thls technology could be a game-changer for people wlth type I diabetes. The key role that the Oxford DRWF Isolation Facility team are playing in these and other'state of the art, studies, demonstrates that we remaln at the leading ed8e of the islet Isolation and islet transplantatlon flelds Internationally. Finally, I would like to relterate my Immense 8ratltude to the DRWF Trustees fortheir ongolng generosity in fundSn8 the Oxford Programme, I can reconfirm myteam's full commitmentto maintaining our successful collaboration and partnership wlth DRWF for many years to come, and to ensure that we will continue to take every opportunity to promote the DRWF misslon in all that we do. Professor Paul Johnson Professor of Paediatric Surgeryi Unlverslty of Oxford Dlrector of the Oxford Islet Transplant Program & DRWF Human Islet Isolatlon Facllity 17 TRUSTEES ANNUAL REPORT FYE2023

DiabE*eS ￿SearCh Et Weltness Foundatlon Research impact Each year, our funded researchers deliver interim and annual reports to demonstrate that their work aligns with the award criteria and progress updates are provided throughout the term of funding. These reports are reviewed by the Research Advisory Board, from which we publish articles in our quarterly Diabetes Wellness News to update our beneficiaries and supporters on the impact that our funding is having for people with diabetes. Here ore two such examples- Unlocking the mystery of Down's syndrome and diabetes Professor Kathleen Glllesple, Professor of Molecular Medicine, Unlverslty of Brfstol, was awarded an £18,000 Pump Priming Grant for the study Does a leaky qut Increase the risk oAdiabetes In chlldren with Down s syndromeP t Whlle most people are famlliar wlth Down's syndrome, many are unaware that children with the condltion are four tlmes more Ilkely to develop type I diabetes. In addltlon, when they do, It tends to strike earlier in thelr Ilves. People with Down's syndrome have an addltlonal copy of chromosome 21; however, from available prevlous research it has not been clear why thls causes them to be at such a heightened risk for developing dlabetes. A DRWF-funded study of 116 babies with Down's syndrome, led by Professor Kathleen Glllesple in Bristol, set out to explore the connection. For parents and guardians of children with Down's syndrome, the findin8s could offer invaluable insights. Key flndln8s of the study • Presence of speciflc antlbodies The research found that antibodles to bovlne serum albumln (BSAI, a food antlgen, were more prevalent in chlldren with Down's syndrome. Simply put, these antibodies might indicate an increased gut permeability or "leaky 8Ut," which some theories suggest mlght be related to autoimmunity and the development of type I diabetes. • Genetic predlsposition Interestingly, chlldren with Down's syndrome and diabetes possess fewer 8enetic rlsk factors for type I dlabetes compared to age-matched children without Down's syndrome. Thls challenges our understanding of the usual genetic predisposltions for diabetes. • Increased autolmmunltyto Insulln Children with Down's syndrome exhibited a heightened autoimmunity to insulin, another indicator of their increased risk of type I diabetes. The research has reinforced the understanding that children with Down's syndrome are more susceptible to type I diabetes and other autoimmune condltions like thyroid autoimmunity. It has further deepened the knowledge on the unique ways this vulnerability manifests in Down's syndrome compared to the general population. Why are these findings important? Knowing that children with Down's syndrome have a higher propensity fortype I diabetes provides an avenue for early Intervention and tailored healthcare. Beyond that, these findings might give clues about the broader mechanic5 of diabetes and autoimmunity. 18 TRUSTEES ANNUAL REPORT FYE2023

Dl3bete5 Reseèrth Et Wellne55 Fou[￿allon Implications and future directions For decades, autoimmunity in children with Down'5 syndrome was a niche topic. However, overthe past five years, the scientific community's interest in understanding the unique health profile of Down's syndrome has surged. There are suggestions that children with Down's syndrome have a heightened response to interferons - proteins that play a critical role in our immune reactions. This heightened response mlght be the key to their increased rlsk of autoimmunity. Moreover, this could also explain why some children with Down's Syndrome develop autoimmune reactions while others do not. The research journey was not without its challenges. The study faced a temporary halt due to Covid-19. However, th15 time was productlvely used for genetic analysls. The researchers also encountered dlfflcultieswith certain laboratorytests, partlcularlythe fatty acld blnding protein 3 test. However, they are committed to overcomlng these challenges and reattempting the test. Lookin8 forward, the research team is 8earlng up to answer a critical question: Why do some Down's syndrome chlldren develop autolmmunlty whlle others do not? This is at the heart of an upcoming grant application and is set to become a focal point for future studies. Concluslon The puzzle of Down's syndrome and diabetes is complex, but we are startlng to flt the pleces together. This study has shed light on some critical aspects of why these children are at a higher risk for type I diabetes. A5 research pro8resses, we are not only understandin8 Down's syndrome better but also getting deeper insights Into the enlgma that Is dlabetes. For children wlth Down's syndrome and their families, thls knowledge offers hope and a path to better, more- informed care. Could our genes hold the key to future diabetes treatments? Dr Sarah Flner. Cllnlcal Senlor Lecturer in Dlabetes and Honorary Consultant In Dlabetes, Blizard Instltute, Queen Mary Unlversity of London. was awarded a £19,771 Pump Prlmlng Grant for the study Uncovering novel, rare genetlc causes of type 2 dlabetes In people of Bangladeshl and Poklstonl herltage partlciputlng in East London Genes and Heolth. Diabetes afferts milllons of people worldwide and its prevalence is partlcularly high among certain communities, such as the Britlsh Bangladeshi and Pakistani populations. While most are familiar with type 2 diabetes, the underlying causes and the intricate science behind it can be complex. Dr Finer'5 recent DRWF-funded study delved deep into the question: what if our genes could offer clues to understandingi preventing and even treating this conditionP 19 TRUSTEES ANNUAL REPORT FYE2023

Diabetè5 Research Er WelinÈss Foundation The Genes t7nd Health study The Genes and Health study Is a large-scale research project focusing on British Bangladeshi and Pakistani volunteers. Historicallyi these communlties have been underrepresented in research studles. The primary goals of this study are twofold: Address the health Inequalltles faced by these comrnunl￿es, such as hl8her rates of type 2 dlabetes and heart dlsease. • Increase the representatlon of these communltles In sclentific research. Wlth more than 55,000 volunteers already partlcipatin8, the study aims to gather insights from 100,000 indlvlduals in total. The role of "knockout genes. Imaglne 8enes as tlny instructlon manuals within our cells. Sometimes, a 8ene misht have a "mlsprint" or error, causlng It not to work properly. These are called 'knockout genes" By studylng Individuals with these genes, researchers have been trying to understand how these rare genetic changes can provide insights into how our body functions and why certaln diseases develop. One of the significant findings from the study revolves around a gene called MC3R Imelanocortin 3 receptor). This 8ene plays a crucial role in how our brain controls our body's development, puberty and growth during childhood. One volunteer with a 'knocked ouv, MC3R gene had delayed puberty, obesity, type 2 diabetes, and was shorter in height. This discovery could help understand the causes of delayed puberty and the potentlal roles of this gene in obeslty as well as dlabetes. The potentlal for future treatments The study flndings are not just academic. By understanding the role of these genes In diabetes and metabolism, researchers hope to identify potential targets for future drug treatments. For example, if a specific gene is found to play a significant role In diabetes, drugs could be developed to target that gene's function, potentially offering a new treatment avenue. The study is currently explorlng other genes related to dlabetes and obesity. Researchers hope thelr investigations will reveal more genetlc causes of these condltlons and possibly identlfy new targets for future drug treatments. Challenges and impllcatlons Like all sc5entific endeavours, the study faced its share of challenges. From changes in scientific collaboration to the global Covld-19 pandemic, the research team had to adapt and pivot. However, despite these challenges, the studV5 implications are vast: Scientific discovery The study has uncovered new areas of biology, providing insights into how our bodies work and the potential mechanisms behlnd dlseases Ilke dlabetes. • Drug development The findlngs could lead to advances in drug development, offering hope for more effective treatments in the future. Broadening research The success of the Genes and Health study has paved the way for other research project5, expanding our understanding of various diseases and conditions. 20 TRUSTEES ANNUAL REPORT FYE2023

Y4• Diabetes R*sÈarch WellftÈss Foundatio The big8er pirture The Genes and Health study is a testament to the power of genetlc research. By understanding our genes, we can gain invaluable insights into diseases like diabetes, offering hope for better treatments and a healthier future. For the Britlsh Bangladeshi and Pakistani communities, this research represents a step towards addressing health inequalities and ensuring that medical advancements benefit everyone equitably, Dr Sarah Finer, principal investi8ator of the study, Said: 'The generous Pump Priming Award made to me by DRWF at a critical Juncture of my career has been invaluable and highly successful. l am very grateful to the DRWF team and those supporting its work flnancially for making this award possible. Global consensus statement endorsement I n 2023, we were asked to endorse a Global Consensus Statement trowards standardizotlon ofperson-reported outcomes (PRO'S) In dlabetes research, This prolect was to address the lack of standardlzatlon/harmonization of PRO'S, limiting the comparability of findings across Studies in a space where too often, patient's perspectives of their lived experlence with diabete5 are lacking as primary or even secondary outcomes in clinical trials. We considered this to be an Interesting and important piece of work glven that clinical outcomes in diabetes are Intimately tied to how the person living with diabetes reacts to and implements treatment recommendations. Whllst DRWF dld notfund or partlclpate In the data revlew project itself, we hosted a Type 2 diabetes patiènt panel to ensure that people with lived experlence were given the opportunity to contrlbute to the narrative around the Importance of person reported experlentlal and clinlcal outcomes, and therefore the global consensus statement Itself. The panel consisted of: Professor Richard Holt Icllniclanl-'Importonce of PRO'S in clinicalcare andoptimizing outcomes,; Dr Mark Evan5 Ire5earcher) - The importance of PRO'5 in clinical research studies which ore integral to design and evaluation to ensure relevance to people with diabetes,; Clalre Levy IT2DI & Chrls Edwards IT2DI - 'How Ilved experience andpsychosocial health Impocts on day-to-day self-management of diabetes,. How we raised our money in 2023 Our approach to fundra151ng-The Trustees are aware of thelr responsibility and accountability to ensure that the charity fundraises legally, responsibly, and effectively. Our plan for 2023 was to maintaln focus on building resilience and sustainabillty for the future through succession plannin8, diversification of income streams and delivery of purposeful programs that continue to meet the ever-changing needs of people with diabetes. 2022 itycome by chanfjol Aciyiil Fundraising continued to be challenging in 2023 and this affected our actual income in the year which was £1,658,853 a shortfall of 6% on our budget expectatlon of £1,760,147 and 6% lower than income received in FYE 2022 at £1,765,756. This was largely related to the reduced volume of dirett mail campaigns that we distributed In the year, which we anticipated would be higher, resulting in a lower response rate/value of donation5 alongside a reduction in legacy income in the year. 21 TRUSTEES ANNUAL REPORT FYE2023

Diabetes RÈsear£h Yrfeur￿ Foundation Corporate Partnerships: We do not endorse products, but we will support initiatives that increase awareness to DRWF and our activitles, and where there is an appropriate message, product, or servlce for people wlth diabetes. To thls end, we have explored meaningful partnership and corporate sponsorship opportunities, where there Is a synergy in mission, vision, and value5. Any potentlal partnership is assessed for feaslbility, compatibility with our own objectives, and rlsk to ensure there is no detrimental effect to our reputation or fundraising potential. Robust risk assessment supports our desire to only engage in suitable and best value partnerships. Detailed discussion and negotlation ensure that the aims of both parties are complementary and mutually beneficial. This maintains transparency and Integrity Sn all partnerships. Professional Fundraisers: Whllst we use the servlces of fundralslng consultants, as and when needed, to advlse on some of our activlties, we dld not work with a professional fundraiser durlng the year. Commerclal participation agreements are In place where necessary. YOU make ALLthe differencel As a charlty that exists almost entirely, at this tlme, on voluntary donatlons and fundralsed income, we are always humbled and heartened by the support that we recelve. Here is a snapshot of some of the communlty actlvltles that took place In 2023 that helped ra15e awareness of diabete5, the charlty and its servlces, 35 well as vltal funds to support all our charitable actlvities - 22 TRUSTEES ANNUAL REPORT FYE2023

OrdbEtes ttesear(h Wellness Foundatir*n A darlnq mother hos supported herlamlly memberfs Ilvlng wlth dlabetes by completlnq afundralslng absell In support OA DRWF. Kathrlne was Insplred to become an enthuslostlc fvndrnlserfor DRWFfollowinq recent diognoses OA type I dlobetes In her Immedlatefvmlly. She recently took part In afvndrnlslng absell chullenqe ond her efforts rnlsed £1,878.13 In support OADRWF the charws artlvftles. SIX years ogo. Kothrlne's husband John Wallls was dlaqnosed wlth type 2 dlabetes at the age of 50. Thls type of dlabetes Is usually Influenced by Ilftstyie, partlcularfy In later Ilfv as Increased welqht can result In lower levels oAlnsulln produrtlon. tt wus not untll thelr 10 year-old son Jonty was dlagnosed wlth type I dlabetes u year ogo that speclallsts thought perhaps he had o late onset of the auto-lmmunefvrm of the condltlon, whlch proved to be the case. Kathrfne who spotted the symptoms a year ago took hlm to thefamlly GP after checklng hls blood sugars. It came as a blg surprlse when her husband's dlagnosls wus chanqed to type I dlabete& She sald.. "I had been looklng afterjohn's dlabetes thmugh dlet, however thls chonqe In dlaqn0515 Was qulte a shock. "John and Jonty realfy support each other In thelr dlabetes Journey. especlolly as they both use the latest contlnuous glucose monltorlng (CGM) technology to help thelr control." Kothrlne has earnedsomethlng of a "daredevll" identity ofter embraclng more whlte-knuckle sponsorshlp artlvities, Includlng a skydlve as well as her recent85m {278fretJ absell down the Portsmouth Swnnaker Tower. Kathrlne sald.. I was Just ple(tsed to be uble to use these chollenges to help DRWFAund more research Into type l and type 2 diabetes ond tools to help people to Stay as well as posslble when lfvlng with allfvrms of dlabetes." 23 TRUSTEES ANNUAL REPORT FYE2023

Dlabete5 Research Ty WelLne55 Foundèrion T14E SPICEISLAND JNN 11 s AJA & STovr, WJNE8 i SPIRITS On Saturday 28th September 2023, following a successful inaugural walk a year prlor, thirty-elght passlonate and enthusiastic fundraisers arrlved at The Spice151and Inn, Old Portsmouth, to walk the coast In Portsmouth. Over the next few hours, walkers from all ages l... and S dogsll made theirway through historic Portsmouth walking the circular 4 or 7mile route. The route was designed to take in sights such as the Iconic Spinnaker Tower, Nelsons Column, and the beautiful Royal Garrison Church, whlch was built around 1212. There was even a designated halfway poSnt, to grab refreshments or skim some stones into the sea something which was enjoyed by the younger members of the walkl The event was a huge succes5 Wlth all walkers finishing in good form and collectively raising a fabulous £2,723 for DRWF through sponsorshlp and donatlons. 24 TRUSTEES ANNUAL REPORT FYE2023

Dlèbetes Reseorch FJ Wellness Fotsndation Dance for Dlabetes returned for its second year as the relationship between DRWF, Hampshire based afterschool provider 'Funkidz Dance, and schools across Hampshire continued to strengthen. th On Friday 26 May 2023, ten schools conslsting of 2,839 participating children took part in DRWF'S annual danceathon fundraiser prior to Easter Half Term. The chlldren spent around 15 minutes per week (for 5 weeks} learnln8 the choreographed dance to a popular song during school hours. The event was a ground shaking success, raising £16,685 In total. This event has a fundralslng split 60140% between DRWF and partlcipating schools. Thls format Is appreciated by the schools that take part provlding thelr chlldren an opportunlty to fundraise In support of a local charity, whilst ra15ing some much-needed income for the schools themselves. DRWF collected £10,011 wlth the remaining £6,674 shared between the partlclpatlng schools. Great fun was had by all. Daneefor Dlabetes will host a performance week in 2024, 8lvlng participating schools more flexibility around thelr academlc tlmetable. th The date ha5 been confirmed a5 Monday 20 - Friday 24th May 2024. More information can be found at 25 TRUSTEES ANNUAL REPORT FYE2023

Diabetes Resear£h Er Wellness FoUThYa￿efi Fundraising Regulator: We are a levy-paying member of the Fundraising Regulator and subscribe to the associated fundraising codes of practice. The charity suppre55es individual supporter records against the Maillng Preference Service, Telephone Preference Service, and the Fundraising Preference Service, whlch helps to ensure that we do not approach individuals who have expressly requested that we do not contact them. Durlng the year, we were notified of 18 FPS requests, which are suppressed from all contact, 22% lower than received in 2022. Complaints: The charity has a published complaints procedure, available on its website, and endeavours to respond to enquiries and complaints wlthin the stated timeframe. Most contacts tend to be a request to opt-out of charity communicatlons by existlng supporters and we monitor the basis on which people request this l.e., content of appeal, volume of contact,. type of contact,. method of contact to Inform our campaigns wlth the aim of reducing any perception of unreasonable intrusion, persistent approach or undue pressure to support. We didn't receive any complaints about our fundralsing practices during the year. GDPR and Data Protectlon: We are commltted to protecting the personal Information and prlvacy of Indivldu31s that we engage with and comply wlth relevant leglslatlon and codes of practlce, whilst carrying out our essential work of raislng awareness of diabetes, providing information and support, and raislng funds. Our privacy poll¢y, publlshed at drwf.or8.uk sets out how we capturei process, manage and retain personal Information. Financial Review Princlpal income strearns in the year were direct mall campaigns; regular giving via dlrect debit; legacy income and gift aid associated with voluntary donations. Management accounts are prepared on a quarterly basis and forecasting reviewed mld-way through the year. Income: Total income was £1,658,853. This was 6% below budgeted income. l£1,760,1471 and 6% less than Income received In 2022 (£1,765,756). Voluntary donations including gift aid receipts at £777,930 was 10.5% less than income received in 2022 (£868,766). Legacy, In Memory & Trust income, having been budgeted for on a 3-year average was £524,625 which was 36% lower than received in 20221£820,553), as expected given the volume and value of legacies received and accounted for in the previous year, Expendlture: Total expenditure was £1,855,067 which was 2% below budget {£1,899,576), and 9% less than expendlture in 2022 (£2,030,351). At year-end we had a deficit of £196,214. This was 41% more than we had anticipated when budgeting forthe year where we had predicted a deficit of £139,156. Whilst expenditure in the year was under budget, the deficit was impacted quite significantly by the reduction in voluntary donations and fundraised income received in the year. Direct charitable expenditure wa5 80p for every £1 spent 181p in 2022). We believe this demonstrates our commitment to spending income on delivering the services for which we exist to provide. Government Grants The charity received E122,458 from the Governmenvs Covid Medical Research Charity Support Fund IBEIS) to support existing fundlng commitment5 of identified early career researchers. Investment Policy Under the Memorandum and Articles of Association, the charity has the power to invest in any way the trustees see fit. The trustee5 are aware and mindful of the Charity Commission CC14 guidance on investments. The trustees, 26 TRUSTEES ANNUAL REPORT FYE2023

Diabetes Research Wellne55 Fovndatlon to minimise risk and having regard to the liquidity requirements of the charityi and to the reserves policy, have historically operated a policy of keeping available funds in a higher interest-bearing deposit account seeking to achieve a rate of deposit interest which matches or exceeds inflation as measured by the retail prices index. The trustees have regularly reviewed opportunities to increase investment return from short-term, easy access, options bearing in mind the desire to ensure that we can react quickly to appropriate requests for additional research support as they arise. The trustees are also con5CiOU5 of on-going cash-flow requirements during a challenging time where hlstorlcal fundraising methods are raising less income and where new methods of fundrai51ng are belng tested at higher cost. All thlngs considered, the trustees believe It appropriate to continue to explore investment opportunities as they present themselves, With a vlew to maximising return on its deposits. In 2023, the Board considered opportunltles to deposlt surplus cash into short-term, hlgher interest-bearlng bank accounts to maximlse Investment return. Multiple deposits were made Into the CAF Charity Deposit platform to the maximum value of £85,000 over a 34-month term durin8 the year, Reserves Policy To safeguard the need for sufficlent funds to cover on going management, administration, and support costs, as well as respond to further grant requests that might arise, the Board aims to maintain unrestricted, free reserves at a level that equals 3-6 months of operating and charitable expendltures1£476,056 - £952,112). At 31, December 2023, the charity held free reserves of £2,231,566 (unrestricted funds less tangible flxed assets). This equates to approximately 14 months of anticipated 2024 operating and charitable expenditures, Whilst this is slgnificantly more than the policy level, the trustees are committed to strengthening existing income streams whilst diversifying fu ndralsing activities to reduce reliance on single sources, It is accepted that this will take investment in activlties where the accuracy of predicting response rates, in terms of volume or value of gift, will be more challengin8 in the flrst instance. Therefore, these additional reserves will enable us to explore avenues of diversification of income streams, and to develop the charity's objective activities for future sustainability. Going concern The trustees conslder that there are no materlal uncertalnties about the charit¢s ability to continue as a going concern. The trustees have made thls assessment for a period of at least one year from the date of the approval of these financlal statements havlng considered known commltments, forecasts and prolectlons and possible pressures on Income generation. After making these considerations, the trustees conclude that there is a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. The charitable company therefore continues to adopt the going concern basis in preparing the flnanclal statements. 27 TRUSTEES ANNUAL REPORT FYE2023

Diabeté5 Rtrsearch WelLness FoondèLiOn Our focus in 2024 and beyond Our focus for 2024 is very much on ensuring that we have the necessary funds to build a resillent and sustainable organisation that can meet the ongolng, and ever-changing, needs of our beneficiarles. Whilst we recognise that the charity sector is a challenging space, with ongoing impact from the cost-of-living crisis and recession, things do appear to be improving a little and this gives us hope. We are intent on reversing the negative impact that both the pandemic and the economic climate have had on our ability to diversify and develop our fundralsing portfolio and deliver Wellness programmes that meet the needs of the diabetes community and the healthcare professionals that look after them. To do thls effectlvely, we plan to- Review current operatlons, processes and procedures to ensure that we are maximising opportunity to create sustainable income streams and beneficiary services. Develop our Wellness Programme actlvities to ensure that they meet need and deliver impactful outcomes whilst maxlmising opportunlty for DRWF to engage in partnerships that deliver revenue and beneflt for all partles. Continue to Identlfy ways in whlch to create cost-efficiencles and effect organisatlonal change within the charlty to make for an or8anisation that can navigate the ongolng challenses and is robust and fit for the future. 28 TRUSTEES ANNUAL REPORT FYE2023

Diabetes Re5eaith ty 5%￿1{Des$ Foundètion Reference and Administratlve Detalls Charity Number: 1070607 Company number: 03496304 Registered Office: Building 1000 Langstone Park Havant, Hampshire P09 ISA Tel: [phone] Webslte: drwf.org.uk Trustees & Dlrectors: Mr W. Michael Gretschel Ichalrmanl Mr John Alahouzos Mrs Valerie Hussey Mr Steve Jones Dr Shivani Misra {retired February 20241 Mr Christian Gretschel Mr Adrian Durelli (elected March 2024) Chief Executlve: Mrs Sarah Tutton (Bonel Advlsers Bankers: Barclays Bank PIC I Churchlll Place London E14 5HP Solicitors: Blake Morgan LLP New Kings Court Toll8ate Chandlers Ford Eastleigh S053 3LG Secretary: Blake Morgan Company Secretary Servlces Audltors: Moore Kingston Smith LLP th 6 Floor, 9 Appold Street London EC2A 2AP 29 TRUSTEES ANNUAL REPORT FYE2023

Olabetes Research Et Wellness Foundation Structure. Governance & Management Governing Document The Diabetes Research and Wellness Foundation, also known as DRWF, is a registered charitable company (Registered Charity No. 1070607 and Company No 034963041 limited by guarantee and govefned by its Memorandum and Articles of Association dated 15 January 1998 and amended by special th th resolutions passed on 15 June 1998, 2nd December 2001 and 24 April 2005. Recrultment & Appointment of Trustees The charity trustees are also the directors of the company for the purposes of company law. As dictated by the charity's Artlcles of Association, directors are appointed by the Company Members, Any person desiring to be admitted to the membership of the company is required to apply in writing. No person shall be admltted untll approved by resolution passed in accordance with the Articles of Association by the existing members, who hold absolute di5cretlon as to the admlsslon of any person. The Trustees of the charity, belng mindful that the board should offer a diverslty of skills to fulfil statutory and fiduciary duties, are open to recommendations for new board members. The buslne5s and medicallhealth related skllls within the exlstlng board member pool are supported by personal experlence of diabetes, which asslsts the board in ensuring that objective activities meet beneficiary need. Addit5onally, the boardls supported In Its decislon-maklng processes by a Research Advisory Board, which has an independent Chairman. The RA8 members review applicatlons and make recommendation for research funding awards. An Editorial Advisory Board provide5 SUPPOrt to the provision of health and social care information, Both boards are made up of clinicians, scientists and other 'experts' in the field of diabetes and related health and strengthen the services that the charity offers its beneficiarles. All board members are 5ubJect to 'conflict of interesy policies and processes. Trustee Inductlon and Tralnln8 - Newly elected Trustees recelve an Induction Pack that outlines the role and responsibilities of the Trustee, along with a hlstory of the structure and purpose of the charity. The pack Includes a copy of the governing document and contact details of all board members. There 15 also an outllne of the Chairman of the Board's role and responsibillties along with detalls of the executive officer taking responsibllity for the daily management of the charity. Trustees are required to comply wlth the eligibility requirements set out by Charlty Commission and to review and update an annual Re8lSter of Interests. Trustees are kept up to date wlth various governance publications and notices from approprlate professional advi50ry memberships. Addltlonally, trustees might be advised of appropriate governance courses that they may benefit from attendlng to ensure diversity and continuity of knowledge and skills within the Board. Newly elected trustees are invited to attend a Revlew Meeting with the chair, after an agreed time lapse, in order to feedback their first impressions and address any concerns. Trustees are actively encouraged to participate in the charity's outreach programme of educational events. Organisatlon - The strategic direction and policy of the charity is the responsibllity of the Board of Trustees. During 2023 slx trustees served on the Board, from a variety of professional backgrounds relevant to the work of the charity. The Board meets routinely throughout the year post-quarter end to review activities and management account5. Additlonal meetings are orEanised as required. Historically, the Board wouSd meet at least once per year in person however this changed during the Covid-19 pandemic due to travel restrictions, with all meetings being held virtually. This has continued during 2023 and there were no meetings in-person during the year. The Chief Executive carries out the daily operations of the charity and is responsible to the Board of Trustees. 30 TRUSTEES ANNUAL REPORT FYE2023

I.) Diabetes rteseèrch Et Weuness Foundatton Connerted & Related Parties - DRWF co-operates on several intellectual matters including sharing articles and reports With the Diabetes Research and Wellness Foundation Inc., a 501C3 Not for Proflt Company operating in the United States; Association pour la recherche sur le diabete {A-rdl in France; Insamlingsstiftelsen Diabetes Wellness Network Sverige (Sweden); Diabetes Wellness Suomi (Finlandl and Diabetes Wellness Norge (Norway). These organisatlons are completely autonomous and independent with no legal connections. Mr, W. Michael Gretschel is the Chalrman of the Board of Trustees of the Diabetes Research and Wellness Foundation and is the volunteer President of the Diabetes Research and Wellness Foundation Inc (USA) but does not serve on its board of directors. He is also a Board member of A-rd (France), DWNS (Sweden), DWS (Finland) and DWN (Norwayl. Mr. John Alahouzos 15 the Chairman of the Diabetes Research and Wellne55 Foundation Inc {USAI and serves on the Board of Trustees of the Diabetes Research and Wellness Foundation IUKI. He is also Chairman of the Board of A-rd (Francel, and a Board member of DWNS (Sweden), DWS (Finlandl and DWN {Norwayl. Mrs. Valerie Hussey serves on the Board of Trustees of Diabetes Research & Wellnes5 Foundation (UK) and Is also an 'alternate memberf on the Board of DWNS1Swedenl. Mr. Chrlstlan Gretschel Is a Board member of Dlabetes Research & Wellness Foundatlon (UK) and also serves on the Board of A-rd (France) The Chief Executive of the Dlabetes Research & Wellness Foundatlon, Sarah Tutton, serves on the Board of DWN (Norway). Llnks between these independent organi5ation5, has proved Snvaluable to the charlty In helplng to strengthen It's internatlonal presence, for the purpose of supporting diabetes research programmes and 8lobal awareness activities. A Reglster of Interests for Board Members and Key Management Personnel is maintained and revlewed on an annual basis. Rernuneratlon Pollcy for senlor staff - The Trustees, who are also the directors, and the Chief Executive Officer comprise the key management personnel of the charity in charge of directlng and controlllng, runnlng and operating the charlty on a day-to-day basis. All trustees give thelr tlme freely and no trustee recelved remuneratlon In the year. Detalls of trustees, expenses are disclosed Sn note 13 to the accounts, Related party transactions are disclosed in note 21 to the accounts. The salary of all staff, Including the chief executlve offlcer, Is reviewed annually and normally Increased In accordance wlth average earnlngs. In vlew of the nature of the charity, its size and structure, the trustees undertake a benchmarking exercise, using onllne research/tools, comparingthe charity's salaries against pay levels offered for slmilar roles within other charities and companies. The benchmark is the mid-point of the range paid for these similar roles with conslderation given to workload, level of responsibility, anticipated rate of inflation and other published research on third sector rates of pay. The charity considers that its remuneration policy- Ensures delivery of the charity's objectives Attract5 and retains a motivated workforce with the skills and expertise necessary to ensure organisational effectivene55. Is equitable and coherent across the organisation. Reflect5 the purposes, aims and values of the charity. Ensures that pay levels and pay increases are appropriate in the context of the interests of our beneficiaries. 31 TRUSTEES ANNUAL REPORT FYE2023

Dittbetes Re5eat¢h Wellness Foukwjatyo Risk Management- The Trustees have examined the major strategic, business, reputational and operational rlsks that the charlty faces. This involves identlfying specific risks,. assessing their likelihood of occurrence and potential impact. determining what steps could be taken to mitigate those risks and delegatlng responsibility to key staff for overseelng management of the associated controls. The risk register is reviewed annually to ensure the adequacy of internal control mechanisms. Our approach to risk assessment and management is evidenced across the organisatlon and throughout our activlties. The risk register was circulated to the Trustees for review and scoring in July and re5ultln8 risks discussed th at a Board meeting held on 19 October. The Board considers that the major risks faclng the charity at present, are- Fundralslng and dependency on slngle Income streams Reserves Competltlon for support Buslness contlnulty IT risk/los5 of data Program development Including activlties outslde of objectlves The past few years have been Incredibly challenglng for all charitles, with clear Impact on fundraising activities and attrltion in channels that, hlstorlcally, have been very solid in their return. The charity is focused on diversifying activltles to reduce reliance on unpredictable or single Income streams. The fundraising landscape is highly competitive at present, wlth more charltiesthan ever applylng for grant funding; Individual donors reviewing thelr financial commitments because of the rlslng cost of livlng; and legacy income, which is an entirely unpredictable income source, contrlbuting a high percentage of overal5 income. We are mindful that fluctuations In Income could Impact on our abillty to deliver direct charltable actlvlties, and so remaln aglle In our approach to protect our aims and objectives. We are monitoring income and expendlture very closely and endeavour to scale back expendlture in line with Income generation where possible. Remote workin8 through the pandemic, as well as diverslfying ourfundralslng actlvities and provision of beneflciary pro8rammes through multiple channels, has heightened our sensitivity to the Impact that a cyber breach could have on the charlty. We rely on public trust and generosity to support our activities, so are mindful of the financial and reputational risk a cyber breach could have. We belleve that we have strong IT systems in place that are fit for purpose but are aware of the ever changing digital/cyber landscape that we are operating in, as well as third sector reports of the volume of cyber breaches that take place in the UK charity sector. Cyber awareness information and trainlng is routinely shared across the organisation as we expand the channels through which we engage with the diabetes community and the wider public. New projectslactivities are reviewed to ensure that they are consistent with our objectives, powers and terms of restricted funding lif applicable), but we are more aware of this morethan ever aswe develop the charitles attivltles to ensure that we remain relevant to the diabetes community and its need5. The trustees consider that the Charity has robust internal procedures, systems and processes and believe that risk a5sessment1s embedded throughout the organisation. 32 TRUSTEES ANNUAL REPORT FYE2023

W•tlD•ss FovndatloD Trustees, responsibllltl¢$ In relatlon to the flnanclal statements- The trustees, who arc also directors of Diabetes Research and Wellness Foundatlon for the purposes of company law. are responsible for preparing the trustees, annual report and the financial stalemenls in accordance wlth appllcable law and Uniled Kingdom Accountin8 Standards (United Kingdom Generally Accepted Accounting Prattlce.) Company law requlre5 trustees to prepare flnancial statomonts for each flnanclal year that 8ive a true and fair view of the State of the affairs of the charltable company and of the outgoin8 resources and application of resources, including the income and expenditure, of the charilable company for that period, In Pfeparlng these financial statement5. the trusttes are re.quired to.. select svitable accountln8 policies and then apply them conslstently. obsèrve the method5 and prirkciples In the Charlties SORP. • make jud8ement5 and estirn3tes Ihat are reasonable and prudent. state whether applicablo UK Accounting Slandards have been lollowed, subject to any material departures disclosed and explained in ihè financial Statements. prepare Lhe f Inancial staternents on the golng concern basls unless It is inapproprlate to presume that the charitable company will continve in business. The trustees are responsible for keeping proper accovntln8 re¢ords that dlsclose wlth reasonable accuracy at any time the f inarcial posilion of the charitable company and enable them to ensure that the financial statements cornply with tho ComDanies Act 2006. They are also responsible for safeguarding the assets of the charitable tompany and hence for takin8 reasonable steps for the prevention and detection of fraud and other irre8ularltles. In sc far as ihe tfustees are aware: there is no relevant audit informatlDn of which the charltable company's auditor is unaware; and the trustees have taken all Steps that they ou8ht to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that informatlon. Audltors - Moore Kin8Ston Smitl LLP have Indlcated their willln8ness to contlnue In olflce and are deemed to be reappointed in accordance with section 487121 of the Companles Act 2006. Small Company Exemptlon- Thi5 report has been prepared In accordance with the speclal provisions of Part 15 of the Companies Act 2006 relating to small companies, On Behalf of the Tr tees Illolo l LOILfr. Daied Mlchael Gretschel Chairman 33 TRUSTfv-F.S ANNUAL REPORT FYE2023

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF DIABETES RESEARCH AND WELLNESS FOUNDATION Oplnion We have audited the finanGial statements of Diabetes Research and Vvellness Foundation ('the company,) for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Summary Income and Expenditure Account, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Republic of Ireland, (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements= glve a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, including its income and expenditure, for th8 year then ended. have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the requirements of the Companies Act 2006. Basls for oplnlon We conducted our audit in accordance with International Standards on Auditing (UK) (ISAS (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibillties for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requlrements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclu51on8 rèlatlng to golng concern In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identif16d any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least ￿e1ve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. other Informatlon The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and. in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 34

We have nothing to report in this regard. Oplnlons on other matters prescribed by the Companles Act 2006 In our opinion, based on the work undertaken in the course of the audit: the information given in the trustees, annual report for the financial year for which the financial statements are prepared is consistent with the fi'nancial statements,. and the trustees, annual report have been prepared in accordance with applicable legal requirernents. Matters on which we are requlred to report by exceptlon In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees, annual report. We have nothing to report In respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion.. adequate accounting records have not been kept, or retums adequate for our audit have not been re￿IVed from branches not visited by us., or the financial statements are not in agreement with the accounting records and retums; or certain disclosures of trustees, remuneration specified by law are not made; or we have not received all the information and explanations we require for our audit. or the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees, annual report and from preparing a strategic report. Respon8lbllltl88 of trustees As explained more fully in the trustees, responsibilities statement set out on page 33, the trustees (who are also the directors of the charitable company for the purposes of company lawl are r&sponsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enablethe preparation of financial statements that are free from material misststement, whether due to fraud or error. In preparlng the financial statements, th8 trustees are responsible for assesslng the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. Audltor's Respon8ibllities for the audlt of the flnanclal statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assuran￿, but is not a guarantee that an audit conducted in accordan￿ with ISAS {UK} will aEways detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial ststements. As part of an audit in accordance with ISAS (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also.. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufFicient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion. forgery, intentional omissions, misrepresentations. or the override of intemal control. 35

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees. Conclude on the appropriateness of the trustees, use of the going con￿rn basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern. Evaluate the overall pr88entation, structure and content of the financial statements, including the disclosures, and whether the financial statements representthe underlying transactions and events in a manner that achieves fair presentation. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, induding any significant deficiencies in internal control that we identify during our audit. Explanatlon as to what Oxtent the audlt wa8 consldored capable of detectlng Irregularltl•8, Includlng fraud rregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misststements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. The objectives of our audit in respect of fraud, are. to identify and assess the risks of material misstatement of the financial statements due to fraud- to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks., and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company. Our approach was as follows.. We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities Act 2011, the Charity SORP, and UK financial reporting stsndards as issued by the Financial Reporting Council. We obtained an understsnding of how the charitable company complies with these requirements by discussions with management and those charged with governance. We assessed the risk of material misststement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance. We inquired of management and those charged with governance as to any known instances of non-complian￿ or suspected non-compliance with laws and regulations. Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of 36

management and those charged with govemance and obtaining additional corroborative evidence as ￿quIred. There are inherent limitstions in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misststement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. Use of our report This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any paty other than the charitable company and charitable company's members as a body, for our audit work. for this report, or for the opinions we have formed. Oor& LziThs£ £.,k4 LLP Date.. 18 Jy.no.29.24 Samir Chandoo (Senlor Statutory Audltor) for and on behalf of Moore Kingston Smith LLP, Ststutory Auditor 6th Floor 9 Appold Street London EC2A 2AP 37

Diabotes Resea￿h and W•lIn￿$ Foundafjon ststement of Flnanclal A¢tivities (Incorporating the Summary In¢ome and Expgndlture Account For the year ended 31 De¢ombor 2023 Unrestrlctod Fund8 2023 TOTAL Unre5tdct•d A￿l￿¢t¢￿ Funds Funds 2022 Fund8 ltt¢omtr Donons and Leg8th$ charl￿￿e ActivitNt other Char[ts￿8 Trading InYe8tment$ Income from Charitable Adlvllios Other Income Totsl Incom• 1,191,928 96,546 44,￿0 29,057 1,362,491 20.775 1 383 266 21,974 253,813 1,213.902 350.159 44.960 29,057 1.838.078 1,536,288 149,476 12.865 8.685 43,319 1,644.533 192.797 12.865 2,704 1,753,299 12.457 1765 756 276.587 1,701.315 12.457 S1.9e4 275 1 658 853 Exp•ndlthm On: R￿Ing Fund8 CharMat4èAGt4vrtlgB Othor 378,648 1.282.e51 378,648 1.476.419 390.93e 1.572,554 390.938 1.839.415 213,568 68.861 841499 213 568 1855 067 1983 49Q 2 030 351 N•t Inc£Kho 25e 233 196 214 249718 264 595 Tr•n•f•r b•tr•••n Fund• 20 Nrt m0￿M*￿t In Fund• 258 233 198 214 249718 284 655 Tot•1 Fund¥ brought forw•rd 2.601.gTS e.e86 2,510.64¢ 2,751,693 23,$42 2.775.235 Totsi ￿rrf#d fonY•rd at 31 ￿¢•m￿oI 2023 224374 2314428 2 501875 2510840 Thor8 w•rn no r•eegnhed galn• orlothwv oth•rthon the deflrjt rèported Icrlh•lnandal y•ar. All ac11￿1•& In th• yeor rdB¢e to ¢onlknuino owralbni. The a￿0MplnY1fig not￿ fom7 thn intogrgl port of th•a•Mnonchl stal•m¢nt$. 38

DSabetes Research and Wellness Foundatlon Balance Sheet As at 310ecembèr 2023 Notè 2023 2023 2022 2022 Flx•d A$8ets Tangible Assets 16 12,175 5,841 CuTr•nt Assets Oebtors Investments Cash 81 bank In hand 17 808,379 424,258 1,463.331 1,205,599 1,703,863 2,695,968 2,909.462 Cfeditord . Amounts lalllng withln on• y•ar 393.717 404.663 N•t Current Assets 2,302,251 2 314,426 2,504 799 2.510.640 Total N•t Ass•ts R•Mrv Resthcièd Fund General ReSe￿e 20 20 70,684 2.243.742 8.665 2,501.975 These financial slatemenls have been prepared In accordance wllh th8 provisiong applScable to companles 8ubieet 10 the Bm811 companies règime v44thin Pprl 16 of the Cumpanie) Acl 2006 6nd with the FRS 102 Char¢ty SORP Tne financial $latemenl$ were approvèd, and auihon8ed for li$tribullon, by th• Tru$iées on 8nd signed on their behalf by. Trusiee Ichagl Gr•tsch•l The accompanying note$ fom on inle9ral part of Ihe$¢ Iinancial slalemenls Comp•ny nurnb•r.' OJ496304 39

Dlabetes Research and Wellness Foundatlon Statement of Cash Flows Forthe year ended 31 December 2023 Note 2023 2022 Cash usod In Op•ratlng Actlvttle8 164,519 (1,005,546) Cash Flows from Ithve8tlng Actlvltles Interest on Bank Depo851 Investments Fixed Assets 29.057 424,258) 9,850 2,704 1405,0511 2,023 681 Calh Flory from Flnanclng Actlvltl Chang• In ¢a8h and c•8h •qul¥alonts In th• y￿r 1240,5321 {1.004,865) Ca•h and ea•h •qulvlent• brought forward 1st January 1.703,883 2,708.728 Ca•h and c••h •qutvalont• at 3l•t D•comb•r 2022 1463 331 1703 863 40

Diabetes Research and Wellness Foundation Notes to the Financial Statements For the year ended 31 December 2023 Accountlng Pollcie8 The financial statements have been prepared in accordance with the Financlal Reporting Standard applicable in the UK and Republic of Ir61and (FRS 1021. The Charitsble Company is a public benefit company forthe purpose8 of FRS 102 and therefore the Charity also prèpared its financial statements in accordance with the Statement of Recomm6nded Practic6 applicable to charities preparing their accounts in accordan￿ with the Financial Reporting Standard applicable in the UK and Republic of Ir81and (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011. The trustees have assessed whether the use of the going concern basis is approprS8te end have considered possible vents or condltions that might cast signifi'cant doubt on the ability of the charity to continue as a going concem. The trustees have made this assessment for a period of at least one year from the date of 8pproval of the financial statements. In particular the trustees have considered the chantys forecasts and projectlons and hav8 taken account of pressures on donations income. After maklng enquiries the trustees have wncluded that there is a reasonable 8xpectation thal the charty has adequate re8our¢es to continue in operational existence for the foreseeable future. The charlty therefore continues to adopt the going concem basis in preparing its finan￿al stalements. The financial ststements are prepared in Stertlng, which 16 the bjnctional currency of the company. Monetary amounts in these financial ststements are rounded to the neare8t pound. The fin8neial statements have been prepared on the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below. Crltlcal accounllng estlmatss and area8 of Judgement In the view of the trustees In applying the 8ccounting policies adopted, no judgement8 wtsre required that have a significant effect on the amounts recognised in the financlal statements nor do any estlmales or assumptions made carry a slgnlftcant risk of materlal adjustment in the next financlal yeer. The principal accounting policies of the company Bre set out below". Income Income is induded on an a¢crua18 basis except that donations under gift aid together with the associated incom8 tsx recoveTies are creditad as income when the donations are retsived. Membershlp Subscriptions are apportion8d across the membership subscripllon period. Income from gift aid repayrnent claims is only included for daims which have been submitted for tax periods ending on or before the year end and when the receipt of this income is Certaln. Legacle8 Legacies are recognised follow¢ng probate and on¢e there is sufficient evidenc8 that receipt is probable and the amount of the legacy receivable can be measured reliably. Where entitlement to 8 legacy exists but there is uncertainty as to rts receipt or the amount receivab18, d8tails are disclosed as a contingent asset until the crrterla for income recognitlon are met. Publlc Donatlons and Glfts.In.Klnd Incoming resources in the form of Gifts-in-Kind are included in the Statement of Financial Activities only when assets donated to th& charity are distributed. Glfts-in-Klnd are donations of commodlties dlrectly usable in charitable programmes, such as food, blankets, books, agricultural and medical supplies. The Charity has an internabonally recognised and accepted monitoring programme in place to ensure that commodities are appropriately valued at wholesale or less, culturally appropriate for the designated programme. and can be both propedy shipped and distributed gratis to the designatéd beneficiaries. 41

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2023 1 Accounting Pollcles (continued) Expendlture Expenditure, which is Charged on an ac¢rual8 b88is, is allocated between: expenditure incurr8d directly in the effort to raise voluntary cOntrib￿lOnS (cost of generating funds). expenditure incurred directly to the fulfilm8nt of th8 charFty's objectives (charitable expenditure)., Charitable expenditure comprises all the expenditure incurred by the charity in meeting its charitable objectives and Is further analysed betsveen.. grants payable in the furtherance of the charity's objectives o costs of actlvlties in furtherance of the charity's objectives o support costs of the charity C08t Apportlonrnènt Where items of expenditure involve more than one cost category these costs have been apportioned on a reasonable basls as detemined by the trustee8. One particular area where the cost is material to the charity is In the production and distribution of direct mailings. One of the purposes of the mail shot is to develop a database of names of people with a partlcular interest in the activities of the Charity and its charitable objects. It is held that ind¢vidual8 who make 8 £10 or greater donation, In response to the mailing, have a degree of interest in diabeles. They are interested because they suffer from diabetes, know Somebody who does or could th8msèlve8 be 8t risk of developing the condition. These are precisely the people whom the charity is trying to help and consequently they Teceive the benefit8 of the educational material provided by the charity. Th886 high interest individuals constitute 25% of the total responses,. 80 the charity allocates 25Q/o of the cost of the m8iling io costs in furtherance of the charity's objects. Furth8rniore the remaining expenditure has been allocated on the basis of whether the educational content of the Individual mailing is significantly high enough so as to be material. When this holds true the remaining cost of the mailing is allocated on a pro•rata basis comparing the education81 content (Costs in furthera￿￿ of the charity's objects) to the fund raising content (costs of generating funds). The educatlonal content is determined by the amount of text and space on each mailing that Is dedlcated to matsrial of an educatlonal nature. Telemarketing expenditure is allocated in a consistent manner wilh mailings, as described above, hence the charity allocates 25tsA of the cost of the telemarketing calls to costs in furtherance of the Charity's objectives, with the remaining expènditu￿ allocaled on the basis of whether the lime spent during the telephone call is in accordance with the charity's objects or othenmise. Fund raising expenditure i.e. Text that may induce a donation from the recipient, is allocaled upon the basis of the volume of the text and space that is not related to text of an educational nature. Support costs comprise all other overhead costs for the running of the charity as an organisation. Fund Accountlng Designated funds are unrestrided funds eamiarked by the Trustees for particular pury)oses. The aim and use of each fund is set out in the notes to the financial statements. Unreslricted funds are donations and other incoming reSoUr￿S received or generaled for expenditure on the general objectives of the charity. Restricted ￿ndS are donations received from a donor who has specified a particular area of the charity's work to which the doriation should be allocated. 42

Dlabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2023 Accounting Policies (continued) Grants Payable Grants are recognised when they become due for payment. Included within the Statement of Financial Activities is the Cost of grant instalments that are payable to charitable organisations l individuals in accordance with the charity's goveming Instruments, together with any grants payable for the year, but not paid by the year end date. The value of grants awarded which are subject to the completion of a future yearfs perfomiance is disclosed as a Financial Commitment in Note 18. Tanglble Flxod A8sot8 and Depreciation Depreciation is calculated to write down the cost less estimated residual value of all tangible fixed assets held for charity use by equal annual instalments over their expected useful economlc lives. The rates generally applicable are.. Office equipment, fixtures and fi'ttings 5-7 years straight line All tangible fixed assets costing more than £250 are capitalised at their cost to the ¢h8rity. Forelgn Currencles Transactions in foreign currencie8 are tran81ated at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. All exchange dlfference8 are dealt with through the statement of financial activities. Leasing Commltments Rentals payable under operating leases are charged against income on a straight line basis over the lease term. Other Flnanclal Instrumonts l. Cagh and cash èqulvalonts Cash and cash equlvalents include cash at banks and in hand and short tonTr deposits with a maturity date of three months or less. 11. Investments Current asset investments include deposit$ with a maturlty date of more than three months. 111. Debtors and Credftor8 Debtors and creditors receivable or payable within one year of the reporting date are carried at thelr at tran8actlon price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest. 43

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2023 Donations and Loga¢lè$ 2023 2022 Don8tions Lottery Programme Legacles Re¢eived 681,335 7,942 524,625 1,213,902 759.181 8,518 820,553 1.588.252 Includgd In the abovo aro ro5trict•d donatlon5 and leg8cle8 of £21,97412022'. £8,6651 Charltable Actlvltle• 2023 2022 Grants Recelved Gift Ald Receipts 261,504 88.655 350,1 $9 48,231 101,247 149,478 Included In the above are r8$thcted grants of £253,61312022.' £43,319} Other Charllabl• Trodln9 A¢tlvltlo• 2023 2022 M8mb8rship Subscriptions Event Fees 8rtd Sponsorghlp 7,392 37,568 44,960 9,336 3,529 12,865 Othèr Incom• 2023 2022 Miscellaneous Income 20.775 20,775 12,457 12,457 Fund Ralslng Co•ts 2023 2022 Caging Carriers Computer Charges Leltershop and Data Postage and Shlpplng Printlng PubllGity Marketlng Costs Community Fundralslng M811 Pack Premiums Lottery Costs Staff Costs Isee Note 12) Sweepstake Wlnners 171,167 3,474 6,034 5,629 38,176 11,665 1,163 185,106 2,086 5,811 6,353 42,000 6,153 1,533 3.025 16.259 31,949 3,847 72,089 16,005 11,220 3,S70 95,745 378,648 390,936 Charltabl• AcUvltl88 2023 Dlrect Ex￿ndIture (Nots 101 2023 Grants Awards (Note 81 2023 Glfts In Klnd (Note 9 2023 Support Costs (Note 11) 2023 Totsl Research into the Rell8f of Diabetes Ral$ing PvblicAwarenes$ of Diabetes 311,343 404,867 716,210 760 209 1,476,419 760,209 760.209 311.343 404,867 2022 Dlrect Expendlturfr INote 101 2022 Grants Award8 (Note 81 2022 Glfts In Klnd (Note 91 2022 Support Costs INote111 2022 Totsl Research into the Relief of Diabetes Raising Public AwaTeness of Dialjetes 275,857 402,394 678,251 961,164 1,639,415 961,164 961,164 275,857 402.394

Dlabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2023 Grant Awards 2023 2022 University of Oxford Cardiff University - Non Clinical Fellowship 2021 Associalion pour la Recherche sur la Diabete University of East Anglia- Clinical Fellowship 2021 University College London - Non Clinical Fellowship 2022 126,407 64,977 133.024 59,563 79,002 66,853 72,418 10,722 337,239 275,927 Les8'. Unclalmed grents wrltten back 125,8981 (70) 311343 275 857

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2023 9 Direct Charitable Exponditur6 2023 2022 Staff Costs {see Note 12) Postage Printing Publicity Mail Pack Premium8 Educational Events Carriers Grant Costs Lettershop and Data 371,825 156,848 68,964 1,505 44,461 81,099 13,766 2,570 396,767 203,382 68.803 11.726 194,318 49,752 12,684 2,083 21,649 760 209 10 Support Costs 2023 2022 Other Staff Costs Professional Costs Management Charge Office Expenses Establishment Expenses Bank Charges and Interest Paid Foreign Exchange (Loss) Depreciation Irrecoverable VAT Amounts paid to Auditors Company Secretarial Fee8 Board Meeting Expenses & Trustee Expenses Other Overhead Costs 3,278 29,097 156,408 72,997 33,194 5,283 5,853 3,516 66,292 22,976 513 180 5,281 404 867 2,048 16,755 159,771 86,995 47,123 5,265 2,717 72,333 22,284 350 2,769 402 394 Support Cost8 are allocated to the Charitable expenditure of the charity in proportion to the direct cost of the activity 11 Wages and Salarles 2023 2022 Wages and Salaries Social Security Costs Pension Costs 419,169 34,355 14,047 467 571 419,928 35,139 13,789 468,856 rhe key man8gement personnel of the charity are the Trustees and the CEO. The totsl amount paid for key management personnel was £71,732 (2022.. £72,124>. 2023 2022 No. No. The number of higher paid employees w8s in the band: £60,000- £70,000 Pension contributions payable for the above individual was £2,776 {2022: £2.776). The number of employees at the end of the year was 13 (2022: 15).

Diabetes Research and Wellness Foundation Notes to the Financial Statsments {Continued) For the year ended 31 December 2023 12 Paymont8 tts Trusteè8 No trustee or person with a f¥mity or business connection with a trii8lee, recefved remuneration In th8 yeaf, directsy or indirectly. from the charity. Reimbursement to Trustee8 for Travel and mee￿n9 C0818 were £nil12022.. £nill. 13 Surplus of Income ov•r Exp•ndltur• 2023 2022 The surplus of income over exFenditure Is slated after charging.. Audilor8' Remunerali¢)n'. Audil Fee relatlng lo the FlnancSal Year In respect ol non aL￿trt 88NIc88 Oper8lino Lease rental8 Plant & Machlnery Other Assets Forelgn Exchange Lo88 Depreciallon 22,900 1,250 21,0 1,140 3.066 16,719 5,853 1,824 24,090 5,265 14 Tuatlon The cornpany, being a regi81ored charlty, Is not Ilable lor corporallon tsx in re8pecl of il¥ eharilable operations for the year. 16 Tanglbl• Flx•d A#*•ts for Ch•rlty U•• •qulpmont, IlxtUrn8 and flttlngB ¢08t At 1 January 2023 Additlon8 In Year Dispo8al$ In Year At 31 December 2023 37,027 11,203 29,274 D•pr•¢latlon Al 1 January 2023 Provided in the year Elimlnaled on Dis￿&￿1 At 31 December 2023 31,186 3,516 6,781 Net 8ook Value At 31 December 2023 At 31 December 2022 16 Debtors 2023 2022 Trade Debtors Other Debtors P￿paYmentS and Accrued Income 68.777 27,424 712,178 808 379 1,920 19,144 1,184,535 1205 599 All Debtors ex￿pt prepayments are financial instruments and are measured at settlement value 47

Dlabetes Rèsoarch and Wellness Foundation Notes to the Financial Statements Icontinued) For the year ended 31 December 2023 17 Credltorn '. Amounts falllng due wlthln one year 2023 2022 Trade Credllor8 Gfanls PayaNe (Bee bal￿ Accru and Deferred Income T8￿￿ Soc[81 Security Olh8r Croditorn 44.805 248.706 82.274 17,932 124,587 210,Y55 54,652 14.260 AJI Cr8dllOTS except dof8rr8d h¢ome 8r8 fhanoal k7strum￿tt afftl aro meaw[￿l al 59tilem8nl vue Rgconelliatlon ofGr4nt• P4y•bl•.' Com￿1￿¥￿11 at 1 Jonu8ry 2023 Gran18 Paygt48 for tho Y88r 1888 Noto 81 GranL% Pd dulng Year 210,￿5 336.rJ8 311.343 273.$92 275.867 401 t38 248 706 In addl￿0Th tQ Ih•8mounts ¢ommttl•(I icer￿d n¢iod above, InJ81866 h8¥8 8180 aulh￿se0 Ihe ￿n11n￿81￿)n oi ¢8rt4ln oronl8 whl¢h ar• 8tA)i•th10 Ihe 4nt rulmung e•rtaln condNlon8. Tho dotolk8 of th880 further commllm•nlo e4n bo found In Note 22. 18 D•f•rr•d Incomo 2023 2022 Dèfèrre(S Incorne BIFWD 181 J•nu•ry 2023 R&￿sSed to In¢ome In Year Income Def6rred In Ytrar Deferred CIFWD 31NI Dg¢¢mtyer2023 3,360 13.3801 54.287 5,972 15,9721 Oafarrld Inceme ty)mprlso8'. . N•vMlgll&r M8mb8rBhlp Subserlptlonts 8ra r81)•wa)￿ 8nrwlly on ¥ rolllng 12 mothhly ba816 - Evenl Regisirallon and Exhlblllon F•è& rthfv•d h advqnce of the e￿nI iaklng plac8 - R•$lrkiod Gr8nts Rocdved that wlll not ba ulllW Lmlll fuiuro p8rlod8 19 R•••rv B•linc• at Trnn•lor from General R••¥rve In Y￿r Incom• In Yoar Exp•ndltur• In Y•r B•l•nc• at 31 D•cemb•r 2023 Mov•mgnt lft Y•ar 202 R?$trt¢led Fund relallng to Qlobel¢$ Rg1e4rch Re8trfcteQ Fwd r￿8￿rt9 lo The Gfve CM6tmas Ch8hnge RgslrfGt8d FL￿d rd8tlng 10 D1•bPl￿ Wellnes$ Day HaTIpoDI D¥•ign818d Growth Fund General Rg$oTr• 253.613 21.974 12Q4.9)81 18.8851 48,710 13,309 48,710 21,974 8,085 2 50197J 1.641499 855 067 2 243 742 Balance al 1 January 2022 Tranil•r from G¢nr41 In In¢om• lo Y•ar Exppndltui• In Yoir Net M0￿ment In Y•ir 8•l•nGO at 31 Drt•mb•r 2022 Y8•r Flestrfctgd Fund relats'ng to Olabetes Research Roiirtctad Ftsnd relaung to Th8 Glve CM8tma$ Chalerye Resirltled Fund Tei4Vng to Dlabet88 Walhes8 D8y H&rUeFwI D8slgnated Growth Fthd Gener81 Re8eNo 43,319 143,3191 123.0421 15CM)I 23,042 500 150,LJJO 114,3771 15001 1150,QOQI 8,685 110D.OLbJl 1713772 1063 490 2.801975 2510640 DI￿n￿ 2023 the charty partlclpated kn the Blg Gfve Chfi$lm&$ Chal8TvJe 202310 ra188 fvnd8 for8 Pump Prfmlng Rasearch Grsnt. Th& funds In the y88rwas £21,97412022 E8.e88}. llurtyi 20¥J th6 tholity received 8 £131,155 or8ntfrom Dlab81e$ Wellnes$ Nth￿rk Sweden for re¥eorch of which £48,710 ￿11 be $pÈnl In 2024. In 2020 Thg trustsas deS￿n￿led £1S0,LYJO lo supwt Ihe grth￿h aTrJ ￿￿er8￿[Call0n of 8cllvthes, Ihis was no k)noor requlred 4) 2022 8nd revefied lo genergl r8swve. Nel A888ts by FIKKI Unrotstrict8d Ro8trfct¢d Tothl Tanglbje As8et8 Cut¥ent As80ts Current Li8bllftles 12,175 2,625,284 393.717 2 243 742 12.17S 2,696.988 393,71 2 314 426 70,684 70.684 48

Dlabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2023 20 Paymonts to Conn•cted Charltlos Nature of R•latlon$hlp 2023 Connectsd Charlty Nature of Tran6actlon$ Total Balaneè at Tothl 8alan¢e at tr8nsactlons tha y#ar ènd tr4n#actlon$ the yearend In th& yèar In th• yèar Dlabetes Research and Wellne$¥ Foundation Inc. 156,408 159.771 Management charges in rÉlation to the shoring of artSdes and staff. This grantwas made to 0SSiSt with the funding of the As50fAatKin's awafenesB and edueatlonal prograrnmos. As50clation P0￿r La Recherche Sur La Diabete 200 Natur• ol R•latlon•hlp• 1 Dlabetes Research and WellneJ8 Foundation In¢. l¥ rJ)mpletely Separate and Ind?pendenl with no legal connadon5, but Mr. John Alahouzos on Board of Truslees ol the a860Ci8ted Charity in the United Stale8. 2 Associab"on Pour La Rechefchè Sur La Dlabettr 18 ¢omple￿Y 8eparats and Indèpondent ￿*th no lèg81 eonneclfon$, bul Mr W.M. Gretsthel and MrJ. A8h¢uzo$ ￿t on the Board of Trust608 Qlthe 88BQCiated charity In FrJnc&. Further detall8 rtyordlno tho rela￿OnshIp can b& found in the Tru8lees ReJx)rt. 21 Fln¥ficlal Commltm•nts Th• charlty ha8 finandal commitrnents ¢1 £404,S1712022.' £621.7751 lor grant8 aUthorfB8d but not accru8d 8B oxp•ndtturo for th8 year ¥nd8d 3108comb8r 2023, a¥ they arts 8ubiect to the Teciplentfvirilllng certain ¢ondltions. The amounts p8y8ble 8re a8 foll¢XY. 2023 2022 Poyabla In 2023 P?y8ble In 2024 Pay&bl8 In 2025 381.522 218,ooe 22,247 382,270 22,247 22 Op•rntlno L•a8e8 At 31st Decemter 2023, the charty ha8 comrnltrnents under operating lea8es a8 foll¢M'. 2023 2023 2022 2022 Wfthln ona Y￿r lo Five Yoars Withln one Year Two lo FSve Yoars Land 8nd Bulklln98 Otr•rAs8ets 24,950 2,433 26,932 1.852 28,000 2,940 21,e33 3,948 Totsl Tle Charftys offlcè th80 commenced on 31st January 2023 with a term ofthree years and a d16countsd period of the Nrst three months ¢urfng whlah th8 rent payable was £nil. 23 R•¢on¢lllatlon of Ngt nthvern•nt In Funds to Net Cmh Flow from O￿Ta￿￿9 ActivIt￿B 2023 2022 Net Movamènt in Funds. SurplusllDèfficit) Add back Dépreciation Charge Deduct Intèrest Ineome Shown irt Invssllng A¢tivKiè& Decrea89 (Inc￿850> in Debt In¢￿Se (Decfeasel In Credlto Nel Cash used in OperatSng ACtivI￿e6 1196,2141 3.516 129,0571 397.220 10,948 164518 1284.595) 2.717 12,7041 le83.7741 77,190 1005 $46 24 h1•mbers' Llablllty The FoundatK)n 18 a company Ilmlte(l ty guar8ntee. In tho av•nt ol W1￿1ng up, the 5 m•mbers' Ik4bility is limited to £1.